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ABSTRACT
Immunoinformatics tools have multiple applications in human immunology research. One of
their most prominent applications is the prediction of T cell epitopes to accelerate vaccine development.
T cell epitopes are short peptides derived from pathogens that are recognized by the cells of the immune
system (T cells) when presented on the surface of cells bound to a major histocompatibility complex
(MHC) molecule, which results in a specific immune response. For their role as key drivers of the
immune response, numerous algorithms have been developed to predict binding of peptides to MHC
molecules; however, comparable tools are limited for other species. The goal of this thesis is to develop
immunoinformatics tools for swine to aid in the design of vaccines for pathogens affecting the pork
industry. One of the main reasons for the limited development of T cell epitope mapping tools for swine
is the lack of data required to train and test the predictive algorithms. Through this research, we have
developed PigMatrix, a tool for prediction of peptide binding to swine MHC molecules. In an initial
analysis, PigMatrix predictive performance was favorable, in particular because its development did not
require training data. Using PigMatrix, we have identified immunogenic peptides conserved in seven
different strains of influenza A virus (IAV), a highly diverse virus that has a significant impact not only
on swine, but also for humans. Protective potential of IAV vaccines is commonly predicted using
genetic data and antibody cross-reactivity properties of the hemagglutinin (HA) surface protein, the
most variable antigen and primary target of the antibody immune response. However, protection has
been reported in the absence of cross-reactive antibodies to HA. To explore the role of T cell epitopes in
vaccine protection, we have developed a method (EpiCC) to compare T cell epitope content between
proteins. We found that the relationship of predicted T cell epitopes between HA sequences of a swine
IAV inactivated vaccine and challenge strains was associated with protection, providing evidence that T
cells contribute to vaccine efficacy. This approach may complement current methods for selection of
influenza vaccines against novel viruses and influenza strains for vaccine development. Taken together,
these findings demonstrate the potential of immunoinformatics tools for the development and
evaluation of swine vaccines and will allow for further research to improve the tools and apply them to
design novel vaccine candidates.
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PREFACE
The following dissertation has been prepared in manuscript format according to the guidelines
of the Graduate School of the University of Rhode Island. The dissertation includes five chapters:
Chapter 1, Introduction. Chapter 2, “Development and validation of an epitope prediction tool for swine
(PigMatrix) based on the pocket profile method”, was published in BMC Bioinformatics. Chapter 3, “In
vivo validation of predicted and conserved T cell epitopes in a swine Influenza model” was published in
PLoS ONE. Chapter 4, “T cell epitope Content Comparison (EpiCC) of swine H1 influenza A virus
hemagglutinin” was prepared for submission to Influenza and Other Respiratory Viruses. Chapter 5,
Conclusions.
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CHAPTER 1
Introduction
Immunoinformatics, also known as computational immunology, is a branch of bioinformatics
that applies computational methods for both basic and translational immunology and vaccine research.
One of the most common applications of immunoinformatics is the prediction of T cell epitopes. T cell
epitopes are short linear peptides derived from pathogen proteins (or self proteins) that are recognizable
by cells of the immune system (T lymphocytes or T cells) and induce a specific adaptive T cellmediated immune response (CMI) [1,2]. They are recognized by specialized antigen receptors on T
cells, T cell receptors (TCRs); however, TCRs only recognize peptides if they are bound to major
histocompatibility complex (MHC) molecules and presented on the surface of cells [2,3]. Due to the
key role of T cells in the adaptive immune response against pathogens, numerous immunoinformatics
tools have been developed to predict human T cell epitopes [4]. However, similar tools are limited for
animals such as swine, cattle, and other important livestock.

MHC molecules
There are two classes of MHC molecules that interact with peptides; MHC class I and MHC class II [3].
These molecules are involved in different antigen presentation pathways and play different roles in the
immune response to pathogens [2,3].
MHC Class I
MHC class I molecules are expressed by all nucleated cells and generally present peptides derived from
intracellular proteins of self and non-self origin [3]. The proteins are initially degraded into peptides by
the proteasome and translocated into the endoplasmic reticulum (ER) by the transporter associated with
antigen processing (TAP) [3,5]. Suitable peptides bind semi-folded MHC class I molecules anchored in
the ER, and induce further folding facilitated by the peptide-loading complex [3,5,6]. Peptide-MHC
complexes are then transported to the cell surface where they are presented to CD8 T cells circulating in
the lymphatic system [3]. Upon TCR recognition of foreign peptides and binding of the T cell surface
co-receptor CD8 to a second constant site on MHC class I, mature naïve CD8 T cells become activated
and differentiate into cytotoxic effector CD8 T cells (cytotoxic T lymphocytes or CTL) [7]. CTL leave
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the lymphoid tissue in high numbers and migrate to infected tissue [8]. The major roles of CTL are to
(1) eliminate infected target cells by inducing apoptosis through release of cytotoxic proteins (perforins,
granzymes) or expressing Fas ligand that binds to Fas on target cells, and (2) secrete cytokines (IFNγ,
TNF-α and TNF-β), which contribute to host defense [2]. Once the infection is cleared, most of the CTL
die, but a minor subset survive and become memory CD8 T cells. These cells are capable of responding
rapidly to any subsequent similar infection [7].
MHC Class II
MHC class II molecules are expressed on professional antigen presenting cells (APC) and generally
present peptides derived from extracellular proteins [2,3,9]. The proteins are first taken into the cell by
phagocytosis or endocytosis, after which endocytic vesicles become acidified, fuse with lysosomes and
then antigens are degraded by proteases (e.g. cathepsins) [3,9]. MHC class II molecules are assembled
in the ER with the invariant chain (Ii) in the binding groove. MHC-Ii complexes are transported to
endocytic vesicles (MIIC) where the Ii undergoes proteolysis, leaving in the cleft the MHC class IIassociated invariant chain peptide (CLIP). In the MIIC, antigenic fragments generated by resident
proteases may bind MHC class II. CLIP has to be exchanged with peptides of higher affinity. CLIP
removal is facilitated by HLA-DM. Peptide-MHC complexes are transported to the cell surface for
presentation to CD4 T cells in the lymphoid system [3,9,10]. TCR recognition of pathogen-derived
peptides bound to MHC, binding of the co-receptor CD4 and an additional co-stimulatory signal
(B7:CD28 interaction), lead to the activation of naïve CD4 T cells, which then differentiate into distinct
CD4 T helper effector subsets that produce diverse cytokines and differentially drive the immune
response. The currently known types of T helper (Th) cells are: Th1 cells, Th17 cells, Th2 cells, T
follicular helper cells (Tfh), and regulatory T cells (Treg) [7]. Th1 cells secrete IFNγ, which activates
macrophages to respond against intracellular viral and bacterial infections. Th17 cells secrete IL-17 to
activate and recruit neutrophils to fight extracellular bacterial and fungal infections. Th2 cells secrete
IL-4 that acts on mast cells, basophils, and eosinophils to respond to parasite infections. Tfh cells
activate naïve B cells to differentiate into antibody-producing cells. Treg suppress other effector CD4
and CD8 T cells. Like CTL, most antigen-specific Th die after resolution of the infection, but a small
percentage of the CD4 Th cells convert to memory cells [7].
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The antigen presentation pathways described above are simplified and exceptions have been
reported [11]. There is evidence that demonstrates that MHC class I and II pathways are not always
separated and that peptides derived from extracellular antigens can end up being presented by MHC
class I molecules (i.e. cross-presentation) [12].
There are important structural differences between the MHC class I and II proteins (Fig. 1) that
determine the specificity of peptide binding. Class I molecules consist of a transmembrane (α) chain
and a β2-microglobulin chain linked non-covalently. The α chain has three structural domains (α1, α2
and α3); the α1 and α2 domains form the peptide-binding groove that is closed at the ends, which limits
the length of peptides able to bind [13]. Ninemer peptides (9-mers) are generally preferred for binding,
but shorter and longer peptides have been reported [3]. Class II molecules consist of two
transmembrane chains (α and β). The α1 and β1 domains form an open ended binding groove. Hence,
longer peptides, generally 13-25 amino acids in length, bind MHC class II [13]. Similarly to class I,
only nine amino acids fit into the groove; the remaining residues on both ends play a role in stabilizing
the interaction [14,15].

MHC genes
Human MHC genes
The genes that encode MHC class I and II proteins are highly polymorphic. In humans, the α chains of
classical class I molecules are encoded by genes in the human leukocyte antigen (HLA)-A, HLA-B and
HLA-C loci. Class II chains are encoded by genes in the HLA-DR, HLA-DQ and HLA-DP loci. HLADRβ chain can be encoded by four loci (HLA-DRB1 and DRB3-5); however, only HLA-DRB1 is
expressed in all individuals. The HLA-DRα chain, which exhibits limited polymorphism, is expressed
from a single locus (HLA-DRA).
Thousands of HLA-A, HLA-B and HLA-C alleles have been reported as well as more than a
thousand HLA-DRB1 alleles [16]. Most of the differences between these alleles can be attributed to
sequence polymorphisms in the binding groove that determine which peptides will be able to bind to a
particular MHC allele. Therefore, different alleles generally have different binding preferences,
although several groups of alleles may have similar preferences [17–19]. Despite their diversity, some
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alleles are more frequently expressed. For example, HLA-A*0201 is expressed by 47% of the European
population based on an allele frequency database [20].
Swine MHC genes
Pigs also express MHC, called swine leukocyte antigen (SLA). Three loci encode the classical SLA
class I (SLA-1, SLA-2, SLA-3) [21]. The expression level of the SLA-1 gene is the highest whereas
SLA-3 is the lowest [22]. Several loci encode genes for expression of SLA class II proteins including α
and β chain genes for SLA-DR and SLA-DQ. Pigs do not express DP proteins. As is true for human
HLA-DRB1, SLA-DRB1 is commonly expressed, and like HLA-DRA, the SLA-DRA locus is highly
conserved [21]. Current methods for the characterization of SLA alleles rely on DNA-based low- and
high-resolution PCR sequence specific primers (PCR-SSP). This method uses allele-specific primers
that cover polymorphic sites unique to a given allele [23]. While high-resolution PCR-SSP identifies
specific SLA alleles, low-resolution SLA-typing differentiates alleles by groups that share similar
sequence motifs [24,25]. SLA molecules are also highly polymorphic. As of October 2016, 116 SLA
class I alleles (including SLA-1, SLA-2 and SLA-3 loci) and 82 SLA-DRB1 allele sequences have been
deposited in the Immune Polymorphism Database (www.ebi.ac.uk/ipd/mhc/group/SLA).

Experimental identification of swine T cell epitopes
Several experimental approaches have been developed to evaluate HLA allele-specific binding
preferences and map human T cell epitopes including intracellular cytokine staining, T cell
proliferation, enzyme-linked immunosorbent spot (ELISpot), and HLA binding assays [26]. In vitro
restimulation of T cells with overlapping peptides is the method most commonly used to identify swine
immunogenic T cell peptides [27–36]. In this assay, peripheral blood mononuclear cells (PBMCs;
consisting of T cells, B cells, dendritic cells, and natural killer cells) isolated from donor blood, exposed
to a particular antigen by natural infection or vaccination, are stimulated with peptides. Peptides of 1520 residues, overlapping by at least 8 amino acids to cover all potential epitope 9-mer cores of an
antigen, are used for stimulation. If the immune system has encountered a given epitope previously, a
specific recall T cell response can be detected by the amount of released cytokines. IFNγ ELISpot assay
is widely used in pigs to measure the frequency of antigen-specific cytokine-secreting cells [32–36].
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Although the ELISpot assay is a very sensitive method to measure epitope-specific immunogenic
responses, its application to identification of T cell epitopes has some limitations. First, under certain
conditions, T cell responses may be limited to a subset of dominant epitopes. For example, responses to
subdominant epitopes may only be detected if the dominant epitopes are absent from the antigen during
exposure or vaccination [37]. Second, T cells that recognize peptides bound to MHC might induce
cytokines different from the one being tested [26,38]. Third, ELISpot assays do not provide information
about the phenotype of cells producing IFNγ [26,38].
SLA binding assays have also been applied to map swine class I T cell epitopes [39–42]. These
assays quantify peptide-MHC affinity, which makes this approach appropriate for identification of
peptide binders and non-binders. Competition assays using a labeled reference peptide bound to an
MHC molecule and increasing concentrations of the query peptide are available for several HLA class I
and II alleles, but they have been developed for only three SLA class I alleles [39–42].

T cell epitope prediction tools
There is a large and ever-increasing body of experimental data on MHC-peptide binding measurements
that has been accumulated over the past few decades, which has enabled the development of highly
accurate T cell epitope prediction algorithms for humans [43]. Epitope-prediction methods use these
large sets of quantitative binding data to first train and then test HLA allele-specific models. Support
vector machines (SVMs), hidden Markov models (HMMs) and artificial neural networks (ANNs) have
been applied to develop predictions for characterized HLA alleles. For the purposes of predicting T cell
epitopes for broad populations of subjects, HLA alleles are commonly clustered into “HLA supertypes”,
based on their binding specificities, reducing the complexity generated by the polymorphism of HLA
genes [17–19].
For uncharacterized MHC molecules with limited or nonexistent experimental data, methods
that infer binding preferences using information about multiple well-studied MHC alleles have been
developed. A common assumption of these “pan-specific” methods is that MHC molecules with similar
contact residues in their binding grooves have similar binding preferences [44].

5

The crystallographic structure of the HLA molecules revealed that the peptide-binding groove
contains a number of pockets and that polymorphic residues in the HLA sequence are often involved in
forming these pockets [13,45]. Consequently, the residues in the pocket define allele-specific binding
preferences for particular amino acid side chains of the antigenic peptides [46]. Thus, for each MHC
molecule, the profile of a given binding pocket can be defined by its residues and binding preferences
[47]. Sturniolo et al. demonstrated that each “pocket profile” was nearly independent of the remaining
HLA-DR binding groove [47]. The authors also showed that an MHC molecule could be defined in
terms of its individual pocket profiles as a quantitative matrix of binding preferences. Therefore, once a
pocket profile is determined experimentally, it can be shared with other HLA-DR molecules that have
identical pocket residues [47].
The pocket profile method has been applied to develop different pan-specific algorithms for T
cell epitope prediction including TEPITOPE [47], TEPITOPEpan [48], PickPocket [49], and EpiMatrix
[50]. Previous studies showed that the predictive performance of pan-specific methods for novel HLA
alleles depends on the similarity of the pocket residues; the performance normally decreases as the
similarity decreases [49]. For HLA alleles with limited quantitative data, algorithms based on the
pocket profile method had better or comparable performance than methods that require a large amount
of data for training (e.g. ANNs) [48,49].

Thesis motivation and outline
The most frequent application of T cell epitope prediction tools is for identification of immunogenic
peptides to design and develop vaccines against a wide variety of infectious pathogens [51–54]. They
have also been applied for development of therapeutic vaccines [54–56], diagnostic tests [57],
deimmunization of biological drugs [58,59], research related to transplantation [60], allergy [61], and
autoimmunity [62]. Although epitope-based vaccines have yet to be licensed, several clinical trials
involving epitope-based strategies are underway (clinicaltrials.gov) [63].
Despite their multiple applications and ability to reduce time, effort and resources required to
identify T cell epitopes [64], prediction algorithms are scarcely available for non-human species. This is
mainly due to the limited experimental data available to develop predictors and may also be due to lack
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of interest in epitope-driven vaccines for livestock animals. However, epitope-prediction tools for swine
could have at least as many applications as for humans and would potentially accelerate porcine
immunology research. One online tool is available for prediction of SLA class I epitopes [65]. This
algorithm was trained and evaluated for prediction of three SLA class I alleles [40,65]. Prediction tools
are not available for SLA class II alleles.
To address the paucity of epitope prediction tools, Chapter 2 of this thesis describes the
application of the pocket profile method to SLA alleles using binding preferences previously defined
for HLA molecules to develop “PigMatrix”. This approach was developed to overcome the lack of
quantitative data required to construct swine T cell epitope predictors. The pocket residues of SLA
molecules were defined based on swine and human MHC crystal structures. Different scoring systems
were tested to determine similarities between SLA and HLA pocket sequences and to identify the best
human match for the purpose of inferring binding preferences of each SLA pocket in the binding
groove. Using this information, matrices were built and their predictive performed tested retrospectively
using datasets of SLA-restricted epitopes that were available for one SLA class II allele and three SLA
class I alleles. For SLA class I alleles, the predictive power of PigMatrix was comparable to or higher
than two other available methods. PigMatrix is the first tool available for prediction of SLA class II
epitopes. These results demonstrated the potential of the pocket profile method and PigMatrix to
develop predictions for SLA alleles without any training step involved, leveraging HLA binding
preferences in order to circumvent training on published ligands as is generally required for quality
predictive models.
In Chapter 3, additional predictive matrices were developed for SLA class I and II alleles that
have been reported to be prevalent in the U.S. swine population [24,25], and applied to identify
potentially immunogenic peptides conserved in seven swine influenza A viruses. The immunogenicity
(i.e. ability to induce an immune response) of 48 predicted T cell epitopes was determined by
measuring IFNγ recall responses using PBMCs from pigs immunized with prototype DNA vaccines
designed to deliver the peptides. Positive responses that were observed upon restimulation with pooled
peptides as well as eleven individual peptides demonstrated that PigMatrix prediction identified SLA
class I and II epitopes. However, it was shown after sacrifice of the animals that there was a mismatch
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between the SLA alleles expressed by the animals in the study and the set of alleles utilized for the
selection of the peptides. Therefore, cohort-specific SLA epitope predictors were developed and used to
re-evaluate binding likelihood of the peptides. Retrospectively, cohort-specific PigMatrix analysis was
able to predict non-immunogenic peptides efficiently.
Influenza A virus (IAV) is an attractive model pathogen to evaluate swine T cell epitope
predictions for several reasons. Importantly, IAV causes a highly contagious disease in pigs that has a
significant impact to the swine industry mainly due to its high morbidity and reduction in the growth
rate of infected pigs, complicating the management of commercial processing [66,67]. Furthermore,
IAV is a zoonotic pathogen that can be transmitted between pigs and people, which is a matter of public
health concern [68]. Swine-origin IAVs can adapt to the human host and spread between humans
resulting in a pandemic, as was demonstrated during the 2009 influenza A (H1N1) pandemic [68,69].
Due the impact of IAV infections in pigs and humans, effective vaccines are highly desirable.
Development of IAV vaccines is a significant challenge due to the variability of the virus.
IAVs are enveloped viruses with negative-sense, single stranded, segmented RNA genomes. The eight
RNA segments of IAV encode two nonstructural proteins (NS1 and NS2), the nucleoprotein (NP), three
RNA polymerase proteins (PA, PB1, and PB2), two polypeptides synthesized from the PB1 mRNA
(PB1-F2 and PB1-N40), the novel PA-X, two matrix proteins (M1 and M2), and two surface
glycoproteins, hemagglutinin (HA), neuraminidase (NA); these two surface proteins determine different
IAV subtypes [69]. Three different subtypes of IAV (H1N1, H1N2 and H3N2) co-circulate and are
predominant in the North American swine population [70]. Reassortment of RNA segments from
different viral strains infecting the same cell (antigenic shift) generates novel IAV strains [70]. Pigs are
considered a “mixing vessel” that produces new IAV strains; they act as an intermediate host in crossspecies transmission of IAV because their respiratory epithelium expresses HA receptors that bind to
both avian and human IAV strains [71]. In fact, most swine influenza viruses are reassortants composed
of mixtures of human, avian and swine virus genes [70]. Accumulation of mutations in HA and NA
(antigenic drift), also contributes to the diversity of swine IAV [70].
Humoral immune response (antibodies) and CMI (comprised of responses from CTL and Th
cells) participate in the adaptive immune response against IAV [72]. Neutralizing antibodies that target
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HA block the attachment of this protein to sialic receptors in the host cells preventing infection [73].
Vaccine protection, mediated by anti-HA antibodies, against a different viral strain depends on the
similarity between the HA proteins of the two viruses. Therefore, variability of HA can reduce the
protective effects of pre-existing antibodies [73]. On the other hand, CMI can be broadly cross-reactive
and protective against variety of IAV subtypes [74–78]. CMI does not prevent infection, but it does
contribute to viral clearance of IAV as well as to reduced clinical signs and viral shedding in humans
and mice [79,80]. Cell-mediated immune responses have also been observed in the lungs of pigs
infected naturally [81], vaccinated with whole inactivated virus vaccine or live-attenuated vaccines [82–
85]. Reduction of morbidity is an important objective for swine IAV vaccines to prevent lack of
appetite and loss of bodyweight.
The genetic relationships and cross-reactive properties of antibodies to the HA proteins of the
vaccine viruses are widely used to predict cross-protection. The hemagglutination inhibition (HI) assay
measures the concentration of serum anti-HA antibodies against a given IAV strain and is commonly
used for predicting protective immunity mediated by neutralizing antibodies to HA [86,87]. However,
there are studies in pigs that show protection (reduced lung lesions, reduced viral titers in lungs and/or
nasal swabs) conferred by swine vaccines even in the absence of cross-reactive antibodies [82,87–91].
In addition, the genetic lineage of the virus does not always predict antigenic phenotype. Therefore,
new means of predicting the protective efficacy of swine IAV vaccines are needed.
To determine the potential role of T cell epitope-driven CMI in protection, in Chapter 4, a
method for comparison of predicted T cell epitope content (EpiCC) was developed. This method was
applied to measure the relatedness, at the T cell epitope level, between the HA from swine IAV strains
representing the major H1 clusters circulating in the North American swine population and those of H1
viruses in a commercial vaccine. Using experimental data from previous efficacy studies testing one of
the H1 viruses in the commercial vaccine against different challenge viruses [82,87–91], a certain level
of T cell epitope relatedness associated with protection was identified. The results showed that the T
cell epitope content relationship deduced from vaccine efficacy studies provides evidence that T cells
contribute to vaccine efficacy. More vaccine efficacy data using diverse vaccine and challenge strains
will be required to further validate and improve the predictive potential of this approach.
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Fig. 1. Comparison of MHC class I and class II crystal structures. (Top; side view) Ribbon
diagrams of class I (HLA-A*0201; PDB id: 3MRE) and class II (HLA-DRB1*0201; PDB id: 1T5W)
MHC proteins. Grey regions are α-domains, orange regions β-domains. The transmembrane and short
cytoplasmic domains, which are not visualized in the crystal structures, extend towards the bottom of
the figure. Peptides (green) bind above the large β-sheet and between the α-helical regions. The domain
organization of class I (α1, α2, α3, β2m) and class II (α1, α2, β1, β2) is different; however, their three
dimensional structures are very similar. (Bottom; top view) Surface representations of MHC molecules
are shown and peptides are represented as spheres. Small conformational alterations and amino acid
substitutions in the peptide-binding site account for the difference in peptide length preference between
class I (8–10mers) and class II (>12mers). The class I peptide has its ends buried in the binding site, and
arches away from the HLA protein in the center. The class II peptide is straight, and extends out of the
open ends of the groove.
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Abstract
Background: T cell epitope prediction tools and associated vaccine design algorithms have accelerated
the development of vaccines for humans. Predictive tools for swine and other food animals are not as
well developed, primarily because the data required to develop the tools are lacking. Here, we
overcome a lack of T cell epitope data to construct swine epitope predictors by systematically
leveraging available human information. Applying the “pocket profile method”, we use sequence and
structural similarities in the binding pockets of human and swine major histocompatibility complex
proteins to infer Swine Leukocyte Antigen (SLA) peptide binding preferences.
Methods: We developed epitope-prediction matrices (PigMatrices), for three SLA class I alleles (SLA1*0401, 2*0401 and 3*0401) and one class II allele (SLA-DRB1*0201), based on the binding
preferences of the best-matched Human Leukocyte Antigen (HLA) pocket for each SLA pocket. The
contact residues involved in the binding pockets were defined for class I based on crystal structures of
either SLA (SLA-specific contacts, Ssc) or HLA supertype alleles (HLA contacts, Hc); for class II, only
Hc was possible. Different substitution matrices were evaluated (PAM and BLOSUM) for scoring
pocket similarity and identifying the best human match. The accuracy of the PigMatrices was compared
to available online swine epitope prediction tools such as PickPocket and NetMHCpan.
Results: PigMatrices that used Ssc to define the pocket sequences and PAM30 to score pocket
similarity demonstrated the best predictive performance and were able to accurately separate binders
from random peptides. For SLA-1*0401 and 2*0401, PigMatrix achieved area under the receiver
operating characteristic curves (AUC) of 0.78 and 0.73, respectively, which were equivalent or better
than PickPocket (0.76 and 0.54) and NetMHCpan version 2.4 (0.41 and 0.51) and version 2.8 (0.72 and
0.71). In addition, we developed the first predictive SLA class II matrix, obtaining an AUC of 0.73 for
existing SLA-DRB1*0201 epitopes. Notably, PigMatrix achieved this level of predictive power without
training on SLA binding data.
Conclusion: Overall, the pocket profile method combined with binding preferences from HLA binding
data shows significant promise for developing T cell epitope prediction tools for pigs. When combined
with existing vaccine design algorithms, PigMatrix will be useful for developing genome-derived
vaccines for a range of pig pathogens for which no effective vaccines currently exist (e.g. porcine
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reproductive and respiratory syndrome, influenza and porcine epidemic diarrhea).

Keywords: PigMatrix, EpiMatrix, Computational vaccinology, Epitope prediction, HLA, SLA, MHC,
class I, class II, Porcine, PRRSV, Influenza, Genome-derived vaccine, T cell epitope
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Background
The interaction of Major Histocompatibility Complex (MHC) proteins with peptides derived from
protein antigens plays a key role in the adaptive immune response mediated by T cells. The
MHC:peptide complex presented on the surface of a cell is recognized by the T cell receptor (TCR),
which activates the T cell and drives the immune response. There are two classes of MHC molecules:
MHC class I presents peptides of intracellular origin to CD8+ T cells (cytotoxic T cells, or CTL) and
MHC class II presents peptides of extracellular origin to CD4+ T cells (T-helper cells, or Th). Both
classes of molecules have similar tertiary structure. Class I molecules have a transmembrane (α) chain
noncovalently associated with β2-microglobulin where the α1 and α2 domains form the peptide-binding
groove; class II molecules have two transmembrane chains (α and β) where the α1 and β1 domains form
the peptide-binding groove. The MHC class I binding groove is closed, which restricts the length of
bound peptides to 8-10 residues; the MHC class II binding groove on the other hand, is open, and
peptides can extend beyond the ends of the groove, allowing binding of longer and more flexible
peptides of variable lengths (typically 13-25 amino acids) [1].
The tertiary structure of MHC molecules is relatively conserved, even across species. For
example, crystallographic studies have shown similarity between Human Leukocyte Antigen (HLA;
human MHC) and Swine Leukocyte Antigen (SLA; swine MHC) molecules [2]. The SLA-1*0401 class
I allele has been crystallized in complex with peptides derived from 2009-pandemic H1N1 (pH1N1)
swine-origin influenza A virus and Ebola virus. A structural comparison revealed that the SLA class I
molecule, SLA-1*0401 contains six pockets in its binding groove, similar to HLA class I molecules.
The root-mean-squared deviation (RMSD) for all of the Cα atoms in SLA-1*0401 and HLA-A*1101,
which has the highest identity with SLA-1*0401 (78%), was <0.7Å indicating a similar arrangement of
their backbones. Furthermore, three out of 23 influenza SLA-1*0401 binders were identical to
previously defined peptides presented by HLA-A*0101 [2]. For SLA class II, no crystal structures are
available, but amino acid SLA-DR sequences are highly similar to their human counterparts. For
example, the amino acid sequences of SLA-DRB1*0201 and HLA-DRB1*0101 are 79% identical.
Due to the importance of peptide binding to MHC molecules in the immune response, human T
cell epitope prediction tools have been developed based on a range of approaches and are widely used
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in vaccine development and experimental immunology [3]. The availability of a large and expanding
database of validated MHC ligands has contributed to the development of more accurate algorithms.
Epitope predictions using these tools reduce the time and effort required to identify T cell epitopes [4].
The number of epitope prediction tools is more limited for pigs due to the paucity of experimental data
available. To overcome the lack of quantitative measurements of MHC interaction for a large number of
HLA alleles, ‘pan-specific’ methods have been implemented for prediction of T cell epitopes that bind
to MHC for which experimental data are limited or not available. Pan-specific methods use
experimental binding data and amino acid sequences of multiple MHC alleles to infer binding
preferences to uncharacterized MHC molecules. These methods have been used for development of
prediction tools for MHC class I [5–7] and II alleles [8–11], but only NetMHCpan has been used for
prediction of SLA class I-restricted peptides [12–16]. This method is based on artificial neural networks
(ANN) trained using as input a pseudo-sequence composed of the polymorphic residues in the binding
groove of a given MHC, a peptide sequence and the experimental affinity data. To our knowledge, there
are no in silico tools that are available for SLA class II.
Sturniolo et al. first described a method for using existing data to develop new epitope
predictors, the pocket profile method, in 1999 [17]. It has been used to develop pan-specific methods
for predicting binding of peptides to HLA class I and II alleles [9, 18]. The approach depends on the
identification of certain polymorphic regions within HLA molecules that are known to be the areas of
contact between peptides and the binding groove of HLA [19–21]. Contact residues from the HLA
molecule that bind the R group (side chain) of a specific amino acid within a linear peptide can be
considered to form a pocket for that R group. Thus, each ‘pocket’ can also be described in terms of its
amino acid binding preferences (‘pocket profile’). The pocket profiles are nearly independent of the
remaining binding groove. So, this method assumes that two MHC alleles with identical pocket residues
will have the same pocket profile. Therefore, given sufficient information about the contact residues of
the set of pockets in the binding groove of an MHC and experimentally determined pocket profiles, it is
possible to compose predictive matrices in silico. The method was originally applied to develop
TEPITOPE, an algorithm for prediction of peptide ligands to 51 HLA class II alleles with known pocket
residues [17] and then extended to any HLA-DR molecules with similar pockets (TEPITOPEpan) [9]. A
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similar method has also been used in the PickPocket algorithm for MHC class I prediction [18].
Whereas TEPITOPEpan uses pocket profiles from TEPITOPE, PickPocket generates binding
preferences using position-specific scoring matrices (PSSMs) from binding data directly. Although no
publications exist using these algorithms for SLA binding predictions, SLA alleles are available for use
in the PickPocket server (www.cbs.dtu.dk/services/PickPocket/).
EpiMatrix is a matrix-based algorithm that uses the pocket profile method to predict potential
HLA class I and II T cell epitopes. The first version of this algorithm was developed in 1996, and newer
versions have been extensively validated in vitro in HLA binding assay and human T cell assays and in
animal studies using HLA transgenic mouse models [22–26]. For common class II alleles, EpiMatrix
appears to predict more accurately than many available epitope-mapping algorithms [27]. Comparative
performance for EpiMatrix class I predictions has not been published; however, the tools have been
successfully applied to identify class I-restricted T cell epitopes in human pathogens [28–30]. The
pocket profile method was used to develop a matrix for a bovine MHC class I allele [31] and in the
early 2000s, this method was also used to derive SLA class II prediction matrices from EpiMatrix, but
this work was not published.
This paper describes the development and retrospective validation of predictive matrices to
map T cell epitopes for SLA class I (SLA-1*0401, 2*0401, 3*0401) alleles and a class II (SLADRB1*0201) allele. “PigMatrix” matrices are built based on the pocket profile method using EpiMatrix
pocket profiles for HLA epitope prediction. While these alleles represent a small subset of commonly
expressed alleles in pigs [32–36], they were selected for their available quantitative peptide data [13–
16, 37–39]. As before, we assumed that predictive matrices developed for HLA alleles should function
as reasonable proxies for the prediction of ligands to SLA molecules with similar pocket profiles. Thus,
we developed ‘composite matrices’ by selecting the most similar HLA pocket (best human match) for
each SLA pocket, and built matrices composed of the corresponding HLA binding preferences (Fig. 1).
Two methods were used to define the pocket contact residues considering different scenarios
of availability of SLA crystal structures. In the first scenario, SLA crystal structures were available, so
pockets were defined from these structures. In the second, no SLA crystal structures were available;
therefore, contact residues were selected based on crystal structures of HLA. We also tested different
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substitution matrices (PAM and BLOSUM) to score pocket similarity to define the best human match.
PigMatrix was benchmarked against existing SLA prediction tools for class I alleles. Benchmarking
against other SLA class II predictors was not possible as no other prediction algorithms are available.
The results demonstrate the potential of this approach to develop matrices to make accurate predictions
for both SLA class I and II alleles for which experimental binding data are limited or even non-existent.

Methods
Datasets
Unique 9-mer peptides with reported binding measurement to a specific SLA allele were compiled from
the literature into two datasets: one comprising binders and the other, non-binders, for each of three
class I (SLA-1*0401, 2*0401, 3*0401) alleles [2, 13–16]. The SLA-1*0401 dataset included 133
binders and 46 non-binders; 2*0401 included 24 binders and 46 non-binders; and 3*0401, 27 binders
and 46 non-binders. Twenty-five (14%) of the SLA-1*0401 peptides were reported by Zhang et al. [2];
the remaining peptides for 1*0401, 2*0401 and 3*0401 were published by Pedersen et al. in different
publications [13–16]. For class II, a dataset was created with peptides specific to SLA-DRB1*0201
from the literature [37–39]. This dataset has 33 binders and 171 non-binders. Peptides with
contradictory (both positive and negative) results were discarded (Supplemental Table 1). Additionally,
we generated a set of 100,000 unique 9-mer peptides from random sequence proteins with the average
amino acid frequencies of the proteins in the Swiss-Prot database for use as a control data set, as
previously described [31]. The random proteins were generated using the RandSeq tool from ExPASy
[40].
MHC sequences
Complete amino acid sequences from SLA proteins, along with HLA class I (HLA-A*0101, A*0201,
A*0301, A*1101, A*2402, A*6801, B*0702, B*0801, B*2705, B*3501, B*4403, B*5101) and class II
alleles (HLA-DRB1*0101, 0301, 0401, 0701, 0801, 1101, 1301, 1501), were obtained from the IPDMHC Database (www.ebi.ac.uk/ipd/). It is important to clarify that the HLA alleles for which binding
preferences are available in EpiMatrix are families of alleles that share pocket preferences, rather than
individual alleles. The alleles represent 12 class I supertypes [41] and eight class II supertypes [42].
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Binding pocket residues
Six pockets (A-F) and five pockets (A-E) were considered for class I and II, respectively. Pockets for
peptide positions 4, 5 and 8 for class I and 2, 3, 5, and 8 for class II were not considered due to their
minimal effect on binding [17, 19, 43]. For each pocket, contact residues (pocket sequences) were
defined as either (1) SLA-specific contacts (Ssc) derived from SLA crystal structures or (2) HLA-based
contacts (Hc) derived from HLA crystal structures (Fig. 2A). The Ssc approach was applied only to
SLA class I alleles using crystallographic data available for SLA-1*0401 (PDB:3QQ3 and 3QQ4) [2].
For Hc, representative crystal structures from HLA class I and II supertype alleles [41, 42] with bound
9-mer (for class I) or longer peptides (for class II) and the highest resolution were analyzed to define the
contact residues (Supplemental Table 2). Four class II supertype alleles (HLA-DRB1*0101, 0301,
0401, and 1501) had crystal structures available.
We considered binding pocket contact residues to be amino acids with atoms within 5.0Å of
those in the bound peptide. Residues were selected using PyMOL (Schrodinger, LLC). Only amino
acids with the side chain oriented towards the peptide were included. Thus, each pocket included the
union of contact residues in all the MHC crystal structures of a given class. For class II alleles, since the
alpha subunit of HLA-DR (HLA-DRA) is practically invariable [44], only residues in the beta subunit
were included. The amino acids in the positions defined as contact residues according to Ssc and Hc
were extracted from HLA sequences and compiled into a pocket library (Fig. 2B), where each pocket is
a non-contiguous sequence of residues ordered by their positions.
Composite matrix construction
Each SLA protein sequence was aligned to a reference HLA sequence (HLA-A*0101 for class I and
HLA-DRB1*0101 for class II) to extract its contact residues (Fig. 2C) based on Ssc and Hc approaches.
SLA pockets were compared to the HLA pocket library to identify the best human match for each SLA
pocket. SLA-HLA pocket similarity was determined using PAM and BLOSUM substitution matrices
for closely (PAM30 and BLOSUM90) and distantly related (PAM120 and BLOSUM62) protein
sequences [45, 46]. For a pocket comparison between SLA sequence x and corresponding HLA
sequence y, both of length N, the similarity score was calculated as the sum of the similarity scores of
each amino acid i using a specific substitution matrix M. The score was then divided by the similarity
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score of the SLA pocket compared to itself.
sim! (!, !) =

!
!!! M[!! , !! ]
!
!!! M[!! , !! ]

The HLA pocket with the highest similarity score was considered to be the best human match
(Fig. 2D). The pocket profiles of the best human matches for each pocket were then combined to form
composite matrices (Fig. 2E).
Matrix validation and performance evaluation
Composite matrices were used to score a set of random 9-mer peptides. The raw binding score
bindraw(p) for each peptide p was calculated as the sum, over a set i of relevant peptide positions, of the
coefficient K[i,pi] of the amino acid pi at position i in p. Positions 1, 2, 3, 6, 7, and 9 were used for class
I and 1, 4, 6, 7, and 9 for class II, as those positions most interact with each SLA pocket.
bindraw p =

![!, !! ]
! ∈!

The average µ and standard deviation σ of the scores were used to normalize scores into a Zscore scale (binding likelihood score).
!=

bind!"# p − !
!

Next, the ability of the composite matrices to separate binders from non-binders and binders
from a set of random peptides was evaluated by comparing the mean of the Z-scores of the datasets
[28]. Differences were evaluated for significance by Wilcoxon-Mann–Whitney test. For class II binders
longer than 10 amino acids, 9-mers overlapping by eight amino acids were scored because in general,
the lengths of MHC binding cores are 9 amino acids [47]. The 9-mer frame with the highest Z-score
was selected to be the most likely MHC binder and its score was used for calculation of the mean Zscore of binders and non-binders. In addition, for each allele, the HLA matrix with the lowest overall
pocket identity with the SLA was used to score both set of peptides, binders and random peptides, as a
negative control matrix.
Peptides in the top 5% of the normal curve, where the Z-score is greater than or equal to 1.64,
were considered to be potential binders. This threshold has been shown to identify peptides that are
highly likely to bind HLA molecules [22]. So as to evaluate the predictive performance of the matrices,
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we calculated the area under the receiver operating characteristic (ROC) curve (AUC) using the
sensitivity and 1 – specificity values for the same dataset of binders and non-binders.
Finally, PigMatrix SLA class I predictions were compared to those of PickPocket 1.1 and
NetMHCpan 2.4 and 2.8. A threshold of 500 nM in binding affinity (or 0.426 prediction score based on
1 – log50K(affinity)), was set to classify binders and non-binders as previously described [6, 18].

Results
Pocket residues
The contact residues that form the binding pockets in SLA were defined from (1) SLA-1*0401 crystal
structures (SLA-specific contacts, Ssc), and (2) HLA class I and II crystal structures (HLA contacts,
Hc). Fig. 3 shows contact residue similarities and differences for SLA-1*0401 in determinations using
Hc and Ssc. Thirty-nine positions were identified with Hc, of which 34 were in common with Ssc
(shown in light blue in Fig. 3) and five were unique to Hc (in orange); there were no positions unique to
Ssc. Several amino acids were involved in more than one pocket; however, this was more frequent for
Hc than Scc due to the nature of the approach; only 23 of the 34 common positions belonged to exactly
the same pockets by both definitions (positions shown in bold and underlined in Fig. 3). Hc included for
each pocket, the union of amino acids over all the HLA crystal structures analyzed. Based on Hc,
positions 97, 99 and 114 were part of four pockets; these residues are located in the central part of the
MHC binding groove and depending on the characteristics of their R chain and the bound peptide, they
can interact with more than one residue of the ligand. We also observed that the total number of contact
residues per pocket was lower in Ssc. The main differences in SLA class I were observed for pockets C
and D where SLA structures had fewer contact residues involved in the binding. Pocket F, on the other
hand, was identical for both.
For class II, only Hc was applied because no SLA-DR crystal structures were available.
Twenty-two positions were considered in contact with ligands; four positions were common to three
pockets, four to two pockets and 14 were involved in only one pocket. Five positions were included for
pocket A, seven in B, seven in C, eight in D, and seven in F (Supplemental Table 3). In pockets B, C,
D, and E, we identified in total eight allele-specific pocket residues; Y30 in pocket B for HLA-

25

DRB1*1501, D28 and R74 in pocket C for DRB1*0301, Q70 and R74 for DRB1*0301 and R13 for
DRB1*1501 in pocket D, and V38 for DRB1*0301 and Y37 for DRB1*0401 in pocket E.
Matrix construction, validation and evaluation
We built composite matrices for each SLA allele and evaluated whether they were able to distinguish
SLA allele-specific binders from non-binders and random peptides (Fig. 4). In some cases, the best
human matches were the same regardless of the approach used to define pocket residues and the pocket
similarity scoring method applied; therefore, prediction results were identical (e.g. Fig. 4 top, SLA2*0401). For SLA-1*0401 and 2*0401, two and four scoring methods respectively, generated Ssc
matrices capable of separating binders from non-binders (highlighted in gray in Fig. 4 top). For these
matrices, mean Z-scores of binders were above the threshold to be considered a potential binder (1.64)
and non-binder Z-scores were below. Furthermore, the difference between the sets of peptides was
statistically significant (p<0.001) using a Wilcoxon-Mann-Whitney test. None of the class I Hc matrices
was able to distinguish with statistical significance binders from non-binders. Likewise, for all SLA3*0401 matrices, mean Z-scores of the binders were either not above the 1.64 threshold or the nonbinders had higher mean Z-scores. For class II allele SLA-DRB1*0201, binders scored using Hc
matrices were above the threshold and were statistically distinct from mean Z-scores of the non-binders
(p<0.01). Negative control matrices for all SLA alleles (using HLA alleles with the lowest overall
pocket identity) did not separate binders from random peptides (means range from −0.57 to 1.13),
showing that the selection of the best human match based on similarity is critical. In sum, these results
show that some composite class I Ssc matrices and class II Hc were able to separate binders from
random peptides and non-binders.
To evaluate the predictive performance of the matrices, we built ROC curves and then
calculated the AUC. For the AUC, a value of 0.5 corresponds to a random prediction and a value of 1 to
a perfect prediction. Fig. 5 shows a comparison of the AUCs of Ssc and Hc matrices, PickPocket and
NetMHCpan. For class I, matrices based on Ssc had higher AUCs than Hc-based matrices. Class I and
II matrices constructed using PAM30 to score pocket similarity had higher AUCs compared to matrices
constructed using PAM120, BLOSUM62 and PAM120, with one exception (Hc SLA-1*0401 built
using BLOSUM62). Compared to PickPocket and NetMHCpan 2.4 and 2.8, PigMatrix’s AUC was
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equivalent or better for SLA-1*0401 and 2*0401; however, due to the nature of the tests, we could not
assess statistical significance. It is worth noting that, in contrast with NetMHCpan 2.8, SLA peptide
data did not contribute to training PigMatrix.
The SLA-3*0401 PAM30-Ssc matrix had the lowest AUC (0.59). This was not unexpected as
matrices for this allele were unable to separate binders from non-binders as described above (Fig. 4).
For these reasons, we examined the binding preferences of the best human matches for the PAM30-Ssc
matrix and compared them to the amino acid frequencies in the sets of binders and non-binders. The
most evident differences were observed in pocket B. The best human match for pocket B was HLAA*0301 (simPAM30 0.49). Of all binders reported for SLA-3*0401, the most common residue in position
two (Pocket B) was arginine, found in 37% of binders, followed by alanine, found in 19% of binders.
These frequencies were more similar to the binding preferences in HLA-B*2705 (simPAM30 0.17) pocket
profile, in contrast to A*0301, which had negative coefficients for arginine and alanine. Based on this
observation, we modified pocket B of PAM30-Ssc matrix from A*0301 to B*2705 (SscModB). This
matrix had a higher AUC (0.81) than the original matrix (Fig. 5). This result showed that predictions
could potentially be improved by selecting best human matches based on similarity in terms of binding
preferences if binding information is available. However, it is important to note that this improvement
in the AUC was specific to the set of peptides available to date, and further prospective studies are
needed to validate the preference of this particular pocket.
Overall, these results demonstrate that matrices built using contact residues from SLA
structures and using the PAM30 substitution matrix to identify the best human match for each pocket,
had the best predictive power of the approaches that were tested. Although the matrices showed
predictive power, the limited number of known binders makes the AUC values less robust. For this
reason, an analysis of a larger dataset of SLA-specific binders and non-binder peptides will be required
to revalidate the predictive power of the matrices.

Discussion and conclusions
Immunoinformatics tools have accelerated the identification of epitopes and design of human vaccines.
However, comparable tools have not been applied extensively to pigs. During the last two decades,
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swine T cell epitope discovery has been based on experimental studies of numerous overlapping
peptides [37–39, 48–54]. While these studies are essential for validating T cell epitope prediction tools,
they can be expensive and time consuming. To reduce experimental effort and expedite the process,
algorithms developed for human T cell epitope prediction have also been used to identify porcine
epitopes [55–57]. However, the substitution of HLA predictions for SLA predictions may not reflect the
fine specificity of SLA binding, which limits the efficacy of this oversimplified approach. To overcome
this, we have developed PigMatrix, a simple yet effective method that leverages available data (SLAbinding peptides, SLA structures and HLA binding data) and pocket profiles already constructed for
HLA-based epitope prediction in EpiMatrix to predict potential T cell epitopes for SLA class I and II
alleles. Using the pocket profile method and the concept that pockets that have similar amino acids will
share similar binding preferences, we built and validated matrices that were able to separate SLArestricted peptides from random peptides and non-binders.
Human pan-specific tools based on the pocket profile method have been described for
prediction of class I (PickPocket) and class II T cell epitopes (TEPITOPEpan) [9, 18]. These methods
defined the amino acids in the pockets from HLA crystal structures. Similarly, we defined SLA-specific
contacts (Ssc) from two crystal structures available for SLA-1*0401. Additionally, we extrapolated the
pocket residues from crystal structures of HLA class I and II crystal structures (Hc). Both approaches
assume for a given pocket that all contact residues are conserved across all class-specific MHC
molecules. However, because there are differences in the pocket residues between MHC alleles and
even between the same allele structures depending on the ligand [2], this simplification is a limitation of
the peptide:MHC modeling approach. Even so, it is a reasonable approximation when structural
information is limited. For class I, differences in the pocket residues using the Hc and the Ssc
approaches were noticeable and impacted the subsequent selection of the best human match to build the
prediction matrices. Matrices based on pockets defined from SLA structure-specific contacts performed
better than HLA-derived pockets. While a definition of the contact residues based on several HLA
structures account for the intra- and inter-allelic variability of binding pockets, it also dilutes the
importance of key residues in the peptide:MHC interaction. We speculate that more allele-specific
pockets could potentially improve the selection of the best human match and therefore the predictions.
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Selection might be also improved by weighting the similarity score by conservation of key contact
residues.
PickPocket and TEPITOPEpan use a method based on BLOSUM62 to calculate a weighted
score of specificity to define the most similar HLA-derived pocket. For PigMatrix, in addition to
BLOSUM62, we used PAM120, which is considered equivalent to BLOSUM62 for comparison of
distantly related proteins [46], to calculate pocket similarity. We also included PAM30 and
BLOSUM90, which are both designed to score similarity between closely related protein sequences.
The SLA matrices with the highest AUC were based on PAM30 using both Hc and Ssc, with only one
exception. If we consider the pocket contact residues as short pseudo-sequences, the better performance
of PAM30-based matrices might be explained because low-numbered PAM matrices are more efficient
for searches involving short sequences. BLOSUM62 on the other hand, performs better to identify
distant homologs using longer sequences. BLOSUM90, like PAM30, is used for closely related
sequences; however, it is not recommended for short peptides [46] and unsurprisingly did not perform
as well as PAM30 in these studies.
Predictive methods for porcine T-cell epitopes are limited, and none existed previously for
SLA class II. PigMatrix is the first tool to make binding predictions for an SLA-DR allele. Class II
predictions were limited to the Hc method because no SLA-DR molecule has been crystallized. Since
SLA-DR-specific binding data are scarce, predictions require further prospective validation. While it is
not possible at this time to benchmark the SLA-DR matrix against other predictors, a comparison can be
made for the SLA class I matrices developed here. NetMHCpan has been used for SLA binding
predictions. PickPocket, which is also based on the pocket profile method, has been described primarily
for HLA class I [18], but predictions are also available for SLA alleles. In this study, for an existing set
of published peptides, PigMatrix performed equally or better than two versions of NetMHCpan and
PickPocket for SLA-1*0401 and 2*0401. While PigMatrix and PickPocket derive SLA binding
preferences from HLA binding data, NetMHCpan artificial neural networks are trained using
information derived from available binding data as well as peptide sequences and MHC sequence
information [6]. It was previously demonstrated that in a scenario where the quantitative binding data
were limited for human and non-human MHC alleles, PickPocket performed better than NetMHCpan
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[18]. This is also evident when NetMHCpan 2.4 results are compared to NetMHCpan 2.8 predictions.
NetMHCpan 2.4 was trained with a limited set of SLA binders and its predictions were equivalent to
random selection (average AUC 0.47). Version 2.8, on the other hand, was trained with more data and
its performance improved for the alleles we evaluated (average AUC 0.76). Conversely, PigMatrix was
not trained with SLA-specific binding data and performed similarly or better than NetMHCpan 2.8
predictions for two of three class I alleles we tested. Moreover, because the number of published
peptides is limited, we were not able to compile a test dataset of peptides known to be different from the
training set used by NetMHCpan 2.8. Hence, it is possible that NetMHCpan 2.8 performance was
overestimated.
For SLA-3*0401, PickPocket and NetMHCpan 2.8 outperformed PigMatrix. Upon closer
analysis, these results provided an example of how PigMatrix could be improved. We were able to build
a better performing model by modifying pocket B in the matrix constructed using PAM30-Ssc. This
might be explained by the role of the amino acid in position two of the peptide as a binding anchor and
its specific interaction with this pocket. It is also worth noting that the HLA pocket library we used was
limited to 12 class I and eight class II supertypes alleles available in EpiMatrix. It is possible that pocket
sequences from other HLA alleles and their profiles are more similar to SLA pockets. Therefore, if the
number of HLA alleles in the library is increased, we might find better human matches for SLA
pockets, which could potentially improve matrix performance.
So as to illustrate the PigMatrix approach, we built initially matrices for only three SLA class I
alleles and one SLA class II allele for which quantitative peptide data were available. These alleles are
commonly expressed in different porcine breeds and cell lines for in vitro culture [32–36]. However,
like HLA, SLA diversity is considerable. These results demonstrate the potential of the approach to be
extended to SLA alleles with limited or nonexistent epitope binding data. Thus, future versions of
PigMatrix will include a more comprehensive and representative set of matrices for SLA alleles
expressed in outbred porcine populations. Moreover, prospective in vitro and in vivo evaluation of
PigMatrix predictions will help to refine the matrices.
We developed the PigMatrix tool with the intent to integrate it into the iVAX toolkit, which is
a comprehensive set of tools for computational vaccine design that includes EpiMatrix, Conservatrix,
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ClustiMer, EpiAssembler, JanusMatrix, and VaccineCAD [58]. When the PigMatrices are used to
substitute for HLA matrices (EpiMatrix) in iVAX, all of the existing suite of iVAX vaccine design tools
can be used with the SLA epitope predictions, which makes it possible to envision accelerated
development of novel T cell epitope-based vaccines or whole subunit vaccines optimized for epitope
content that protect against infectious disease in swine.
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Pocket A

Pocket B
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Target SLA allele
Fig. 1. Illustration of PigMatrix development using the pocket profile method. Three pockets (A, B,
and C) from human (HLA) and swine (SLA) MHC molecules are represented as different shapes and
colors. The contours of the pockets are shown in bold black lines. HLA pockets from two HLA alleles
(HLA-A*0101 and B*4403) are shown in the first two rows. For each pocket in a target SLA, in the
third row, we identified the most similar HLA pocket (best human match) and combined their pocket
profiles (binding preferences expressed as coefficients) to build composite predictive matrices
(PigMatrix).
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Fig. 2. PigMatrix algorithm. (A) Residues in contact with the peptide are determined with respect to a
crystal structure of either an SLA allele (Ssc) or an HLA supertype allele (Hc). Class I supertype alleles
are represented by three HLA molecules. (B) Contact residues defined by either Ssc or Hc are extracted
from HLA sequences and compiled into a library of HLA pockets (HLA pocket library). Pocket A
positions and the extracted pocket sequences for Ssc and Hc are marked with *. (C) For a target SLA
allele, contact residues (defined by Ssc or Hc) are identified by aligning the SLA sequence to a
reference HLA sequence. (D) SLA pocket sequences are compared to those in the HLA pocket library
to identify the best human match. (E) Binding coefficients of the best human match for each SLA
pocket sequence are compiled to build a PigMatrix. Coefficients are represented in red to blue scale
(high to low binding likelihood).
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Fig. 3. Comparison of contact residues in the binding pockets based on SLA-specific contacts
(Ssc) and HLA contacts (Hc). Top: Schematic representation of the crystal structure of SLA-1*0401
(PDB:3QQ4; residues 1 to 181 rendered with PyMOL (Schrodinger, LLC)) showing the residues
involved in the binding pockets. SLA contact residues and the ligand (ATAAATEAY, yellow) are
represented as sticks. Residues common for both Hc and Ssc approaches are show in light blue; residues
unique to Hc in orange. Bottom: Positions in the SLA binding pockets are shown. The first column
(SLA position) is the residue and position number in the SLA-1*0401 protein sequence
(Genbank:2352988). Residue positions shown in bold and underlined are identical (i.e. amino acid
involved in the same pocket(s)) for both approaches. Positions in light blue are common for both
approaches; positions in orange are unique to Hc. The next columns show, shaded in gray, the positions
involved in pockets A through F that interact with relative ligand positions (peptide position). The last
column (Count) is the number of pockets in which an amino acid participates. The last row (Total) is
the total number of residues in each pocket.
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Fig. 4. Validation of composite matrices. Top: Binding likelihood (Z-score) means and standard
deviations (sd) of binders and non-binders calculated using the matrices built based on Ssc and Hc and
different scoring methods for pocket selection are shown for SLA class I and II alleles. Z-score means
and sd calculated using negative matrices, HLA matrices with the lowest overall pocket identity for
each SLA allele, are also shown. Instances where the Z-scores of binders and non-binders were
statistically different (p-value ≤ 0.05) using a Wilcoxon-Mann–Whitney test, are shown in bold; those
with Z-score means above or below 1.64 for binders or non-binders, respectively, are shown in gray.
Bottom: Comparison of binding likelihood (expressed as Z-score) between matrices (PAM30-Ssc and
Negative) shown as density estimates (smoothed histograms). Note that y-axes are differently scaled.
Binders and non-binders were scored with PAM30-Ssc (for class I), PAM30-Hc (for class II) and
Negative control matrices. 100,000 natural random 9-mers were scored with either PAM30-Ssc (class I)
or PAM30-Hc (class II). The black line indicates the threshold at which a 9-mer is considered a
potential binder (Z-score of 1.64). Ssc was not applied to SLA-DRB1*0201 because crystal structures
are not available.
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Fig. 5. Matrix performance comparison. AUCs of the matrices built for SLA class I and II alleles are
shown. The highest AUC for each method is shown above the bars. For SLA-3*0401, AUC of SscModB,
a PAM30-Ssc matrix with a pocket B profile different than the best human match, is shown in a dashed
rectangle to illustrate the impact of pocket B. If one or more matrices for the same approach (Ssc or Hc)
have equal AUC, it is indicated with *.
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Abstract
Swine influenza is a highly contagious respiratory viral infection in pigs that is responsible for
significant financial losses to pig farmers annually. Current measures to protect herds from infection
include: inactivated whole-virus vaccines, subunit vaccines, and alpha replicon-based vaccines. As is
true for influenza vaccines for humans, these strategies do not provide broad protection against the
diverse strains of influenza A virus (IAV) currently circulating in U.S. swine. Improved approaches to
developing swine influenza vaccines are needed. Here, we used immunoinformatics tools to identify
class I and II T cell epitopes highly conserved in seven representative strains of IAV in U.S. swine and
predicted to bind to Swine Leukocyte Antigen (SLA) alleles prevalent in commercial swine. Epitopespecific interferon-gamma (IFNγ) recall responses to pooled peptides and whole virus were detected in
pigs immunized with multi-epitope plasmid DNA vaccines encoding strings of class I and II putative
epitopes. In a retrospective analysis of the IFNγ responses to individual peptides compared to
predictions specific to the SLA alleles of cohort pigs, we evaluated the predictive performance of
PigMatrix and demonstrated its ability to distinguish non-immunogenic from immunogenic peptides
and to identify promiscuous class II epitopes. Overall, this study confirms the capacity of PigMatrix to
predict immunogenic T cell epitopes and demonstrate its potential for use in the design of epitopedriven vaccines for swine. Additional studies that match the SLA haplotype of animals with the study
epitopes will be required to evaluate the degree of immune protection conferred by epitope-driven DNA
vaccines in pigs.

Keywords: PigMatrix, epitope prediction, T cell epitope, Immunogenicity, Swine, influenza, influenza
A virus, vaccine, immunoinformatics, Swine Leukocyte Antigen, SLA, iVAX, class I, class II
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Introduction
Swine influenza is a highly contagious respiratory viral infection in pigs that has a major impact on
their health. In addition, influenza outbreaks are responsible for significant financial losses to pig
farmers, large and small, on an annual basis [1]. The negative economic impact is due to weight loss,
reduced weight gain and predisposition to other infections [2]. Clinical signs of the disease include
fever, coughing, sneezing, nasal discharge, lethargy, and anorexia. The causative agent is influenza A
virus (IAV), a negative-sense, single-stranded, segmented RNA virus of the Orthomyxoviridae family.
Transmission is by direct contact and by aerosol [3]. As is true with IAV in humans, antigenic drift by
accumulation of mutations and/or antigenic shift by reassortment with genes from other IAV subtypes
results in the emergence of novel influenza viruses [4]. Human-to-swine ‘spillover’ events also
contribute to the genetic diversity of swine IAV [5]. H1N1, H1N2, and H3N2 swine IAV subtypes are
endemic and co-circulate in swine in the U.S. [6].
Continual reassortment events led to the emergence of a novel triple-reassortant internal gene
(TRIG) cassette that contains internal genes derived from human (PB1 gene), avian (PA and PB2
genes) and swine (NS, NP, and M genes) IAV viruses [7]. The TRIG is conserved among swine IAV
circulating subtypes and it seems to have the ability to combine with numerous hemagglutinin (HA) and
neuraminidase (NA) genes, including those of human and swine origin leading to enhanced strain
variability [7]. Thus, the primary antigenic component of swine IAV vaccines is HA, which has evolved
to present antigenically distinct HA lineages including: (1) the classical swine lineages, H1α, H1β,
H1γ, H1γ-2, H1pdm09; (2) lineages derived from human seasonal H1 viruses, H1δ1, H1δ2; and (3) H3
cluster I-IV viruses [6,8,9]. This marked genetic diversity complicates the development of effective
vaccines for pigs.
The predominant type of vaccine used by pork producers consists of whole inactivated viruses
(WIV), administered with adjuvant by intramuscular injection. HA is the primary target of protective
antibody responses of this platform. These vaccines are problematic for three reasons. First, antibody
induced by WIV vaccination does not provide significant protection against antigenically diverse strains
of IAV [8,10]. Second, WIV vaccines have been linked to vaccine-associated enhanced respiratory
disease (VAERD) in pigs when WIV vaccine and infecting strains are mismatched [11–13]. Lastly,
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existing vaccines do not adequately address viral diversity.
In contrast, cell-mediated immune responses to epitopes that are conserved across IAV strains
have been shown, in a number of studies, to be protective against influenza. For example, human and
mouse studies demonstrate that cell-mediated responses to conserved non-structural proteins can be
broadly cross-reactive [14] and protective against variety of IAV subtypes [15]. Both CD4+ T helper
cells (Th) and CD8+ cytotoxic T cells (CTL) contribute to clearance of IAV [16–18]. T cell help is also
required for the development of high titers of strain-specific antibody [18]. In fact, memory T cell
response improves vaccine efficacy against emerging IAV strains when cross-reactive helper T cell
populations are present from prior infection and/or vaccination [19]. CTL responses have also been
associated with viral clearance and reduced clinical severity in mice and humans [20,21]. Our group has
been interested in the role of cross-conserved epitopes in protection against IAV in human populations,
and has postulated that immunity to cross-conserved epitopes may have contributed to attenuation of
morbidity in some age groups during the 2009 H1N1 IAV pandemic [22].
Adaptive cell-mediated immune response depends on T cell receptor (TCR) recognition of
peptides bound to major histocompatibility complex (MHC) molecules presented on the surface of
cells. Immunoinformatics tools have accelerated the discovery of T cell epitope peptides and design of
epitope-driven vaccines (EDV) for human IAV [23–26]. The lack of quantitative MHC binding data has
limited the development of tools for swine, cattle, and other food animal species. We recently
developed a new tool for swine epitope prediction (PigMatrix) that leverages the pocket profile method
originally described by Sturniolo et al. [27]. We integrated the new swine MHC predictions into iVAX,
the suite of tools for vaccine design that were validated in a number of pre-clinical studies of human
vaccines [28,29]. This set of tools is particularly useful for identifying T cell epitopes that are conserved
across subtypes of strains [30], which is relevant to develop a IAV vaccine for pigs. Having integrated
the new matrices into this ‘in silico vaccine design’ platform, we were able to apply the PigMatrix
version of iVAX to IAV.
In this study, we used PigMatrix to predict class I and II T cell epitopes that are conserved in
external and internal proteins from seven circulating IAV strains. We selected epitopes predicted to
bind to SLA alleles that were previously reported to be prevalent in outbred U.S. swine populations
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[31,32] and developed a prototype PigMatrix epitope-driven DNA-vaccine (PigMatrix-EDV) as a tool
to evaluate immunogenic responses to highly conserved predicted epitopes in a swine IAV model.
PigMatrix predicted peptides induced specific interferon gamma (IFNγ) recall responses in pigs
immunized with the prototype PigMatrix-EDV encoding strings of class I and II putative epitopes. In
addition, we performed a retrospective analysis to compare IFNγ responses to individual peptides (28
class I and 20 class II peptides) with predictions specific to the SLA expressed in the study cohort. The
results showed that cohort-specific predictions using PigMatrix, were particularly effective for
identification of non-immunogenic peptides.

Materials and Methods
Sequences
Gene

sequences

of

A/California/04/2009

proteins

expressed

by

seven

(H1N1)

(H1N1pdm09),

representative

swine

A/swine/Illinois/5265/2010

IAV
(H1N1)

(pandemic
(IL/10),

A/swine/Ohio/511445/2007 (H1N1) (OH/07), A/swine/Minnesota/02011/2008 (H1N2) (MN/08),
A/swine/Minnesota/A01301731/2012 (H1N2) (MN/12), A/swine/Texas/4199-2/1998 (H3N2) (TX/98),
A/turkey/Ohio/313053/2004 (H3N2) (OH/04)) [33,34] were downloaded from the Influenza Virus
Resource [35] (Supplemental Table 1).
Conservation analysis
The goal of the conservation analysis was to identify highly cross-conserved 9-mer peptides. Since 9mers fit into the SLA binding groove [36], proteins derived from IAV genomes were parsed into 9-mer
frames overlapping by eight amino acids using the Conservatrix algorithm [30]. Nine-mer sequences
were searched for identically matched segments among IAV strains, as previously described [28].
Resulting 9-mers were ranked by their conservation within the dataset.
T cell epitope prediction
Using the pocket profile method [27] and well-defined EpiMatrix binding preferences for human MHC
pockets, we developed PigMatrix prediction matrices as previously described [29]. Matrices were
designed based on the binding preferences of the best-matched Human Leukocyte Antigen (HLA)
pocket for each SLA pocket. The contact residues involved in the binding pockets were defined from
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crystal structures of SLA or HLA supertype alleles for class I and II, respectively. Allele selection was
based on prior data indicating their prevalence in outbred swine populations [31,32]. Matrices were
constructed to predict T cell epitope binding to class I (SLA-1*0101, 1*0401, 2*0101, and 2*0401) and
class II (SLA-DRB1*0101, 0201, 0401, and 0601) SLA alleles. SLA-1*0401, 2*0401 and SLADRB1*0201 were previously validated using published epitopes [29]. We also developed matrices for
SLA alleles expressed in the study cohort (cohort-specific prediction) to perform a retrospective
analysis.
All highly conserved 9-mers resulting from Conservatrix analysis were scored for binding
potential against the panel of SLA alleles. PigMatrix raw scores were standardized to Z-scores to
compare potential epitopes across multiple SLA alleles. Peptides with Z-scores above 1.64 (the top 5%
of any given sample of 9-mers) were identified as likely to be SLA ligands. The final selection of
putative SLA class I-restricted epitopes was based on PigMatrix score (Z-score>1.64), SLA class I
allele coverage (≥50%) and IAV strain coverage.
Construction of immunogenic consensus sequences
EpiAssembler was used to construct 16-25 amino acid length SLA-DRB1-restricted sequences that
were highly conserved in IAV strains, promiscuous (predicted to bind to multiple alleles), and enriched
for immunogenicity (immunogenic consensus sequences or ICS) [28]. The density of predicted binding
motifs in each ICS was scored (i.e. cluster score) using ClustiMer [28]. The cluster score represents the
deviation in predicted epitope content from baseline expectation based on random peptides [37]. ICS
with cluster scores above 10 were considered to be high-quality clusters for inclusion in the prototype
vaccine. Peptides were ranked based on cluster score and IAV strain coverage and the final selection of
epitopes was made using the same three criteria described above for class I peptides. Highly
hydrophobic peptides were excluded as these are known to be more technically difficult to synthesize
and may be less soluble in aqueous solutions.
Multi-epitope plasmid DNA vaccine engineering and production
Predicted epitope sequences were concatenated to form two multi-epitope genes (one for SLA class I
and one for class II epitopes). VaccineCAD [38] and a concatemer optimization algorithm
(unpublished) were used to rearrange the peptides to avoid creation of novel epitopes at peptide
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junctions and to search for transmembrane helices that might interfere with production of the epitope
concatemer proteins. Both algorithms, VaccineCAD and the concatemer optimization algorithm, used
PigMatrix to predict junctional epitopes.
Transmembrane helices were predicted using TMHMM 2.0 [39]. In addition, where reordering
did not sufficiently reduce the potential for junctional immunogenicity, a cleavage promoting spacer
(‘AAY’) for class I-restricted constructs [40] or a binding inhibiting ‘breaker’ sequence (‘GPGPG’) for
class II-restricted constructs [41], was introduced between peptides to optimize epitope processing. Two
genes (one for class I and one for class II epitopes) predicted to have no transmembrane segments or
junctional epitopes, were codon-optimized and synthesized by GeneArt (Life Technologies, NY, USA).
Tandem stop codons were incorporated downstream of the epitope sequences. Class I and class II
genes, respectively, were subcloned at predefined flanking restriction sites downstream of either a
destabilizing UbiquitinA76 tag (UbA76) in pNTC8684-eRNA41H for proteasome targeting and a tissue
plasminogen activator (TPA) leader sequence in pNTC8682-eRNA41H (Nature Technology
Corporation, NE, USA) for secretory pathway targeting. High-purity plasmids for immunizations were
prepared by Nature Technology Corporation, Inc. at research grade. Each plasmid underwent quality
control testing including spectrophotometric concentration and A260/A280 ratio determination (1.97),
restriction digest analysis to assure the presence of the multi-epitope genes, agarose gel electrophoresis
determination of residual host RNA and DNA (none detected), and quantitative endotoxin testing (<2.0
EU/mg).
Peptide synthesis
Peptides corresponding to putative epitopes in the DNA vaccine were synthesized using 9fluoronylmethoxycarbonyl (Fmoc) chemistry by 21st Century Biochemicals (Marlboro, MA). Peptide
purity was >80% as ascertained by analytical reversed phase HPLC. Peptide mass was confirmed by
tandem mass spectrometry.
Immunizations
Thirty-two, 3-week old outbred pigs from a high-health status herd known to be free of IAV were
delivered to the USDA-National Animal Disease Center. To ensure that prior exposure to IAV resulting
in immunity was absent, all of the pigs were screened for influenza A nucleoprotein antibody by ELISA
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(MultiS ELISA, IDEXX, Westbrook, Maine) prior to the start of the study. All of the study pigs were
treated with ceftiofur crystalline-free acid (Excede; Zoetis Animal Health, Florham Park, NJ, USA) and
enrofloxacin (Baytril 100; Bayer HealthCare AG, Monheim, Germany) upon arrival to reduce bacterial
contaminants. The experimental outline is summarized in Fig. 1. Pigs were randomly distributed into
four groups of eight and housed in separate isolation rooms in animal biosafety level 2 (ABSL-2)
containment. Three groups were vaccinated: (i) one group of eight pigs was vaccinated with the
prototype PigMatrix DNA-vaccine as the initial prime vaccination, followed by two homologous boosts
at 21 and 42 days post-initial vaccination (dpv) (PigMatrix-EDV); (ii) one group of eight pigs was
vaccinated with empty DNA plasmids containing no epitopes (Sham); (iii) one group of eight pigs was
vaccinated with commercially available FluSureXP® administered 21 days apart, according to the
manufacturer’s directions (Zoetis Animal Health, Florham Park, NJ) (FluSure). FluSureXP® contains
whole inactivated γ-cluster H1N1, δ1-cluster H1N1, δ2-cluster H1N1, and cluster IV H3N2 swine IAV
viruses. The final group of eight non-vaccinated pigs served as controls (NV). The prototype PigMatrixEDV plasmids were thawed at 4°C overnight, combined and administered intramuscularly in the
postauricular region of the neck by needle stick injection with 4 mg per DNA plasmid in 4 mL of TrisEDTA (TE) buffer (2 mL on right side and 2 mL on left side).
Animal care
Animals at the National Animal Disease Center (NADC) are cared for in accordance with the guidelines
set forth in the “Guide for the Care and Use of Laboratory Animals” (National Academy Press, 1996)
and in regulations and standards as promulgated by the Agricultural Research Service, USDA, pursuant
to the Laboratory Animal Welfare Act of August 24, 1966, as amended. Animal studies are reviewed
and approved by NADC’s Institutional Animal Care and Use Committee (IACUC). In addition, the
IACUC is federally mandated to review, at least once every 6 months, the research facility's animal care
program and physical facilities per USDA regulations and using the “Guide for the Care and Use of
Laboratory Animals” as the basis for review. Full-time animal caretakers, technicians and supervisors
and on-call veterinarians perform routine animal care, as well as weekend/holiday activities and
respond to emergencies. NADC staff members who worked with the animals have backgrounds and
continuing training in the appropriate, species-specific care and handling of research animals. Training
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courses for animal staff include safe handling skills, animal welfare, specific procedures (e.g. bleeding),
personal protective equipment (PPE) requirements, as well as proper handling and care and use of
anesthetics and analgesics. For this study, animals were housed in an ABSL-2 facility (12 h light/dark
cycle) during the course of the study, and humanely euthanized at the termination of the project with a
lethal dose of pentobarbital (Fatal Plus; Vortech Pharmaceuticals, Dearborn, MI). Protocols were in
place to humanely euthanize any animals if unforeseen clinical disease presented, such as severe
lameness or depression that results in recumbency with reluctance to stand, although that did not occur
in this study (all animals in the study were terminated at the end of the experiment). Animal
observations and feedings were completed at least twice daily by personnel who have been trained to
look for signs of illness or abnormalities, at which time the veterinarian on-call and the principal
investigator would have been notified.
Measurement of IFNγ response by ELISpot assay
At 42, 49 and 63 dpv, whole blood was collected by venipuncture and peripheral blood mononuclear
cells (PBMC) were isolated as previously described [42]. The frequency of epitope-specific T cells was
determined by porcine IFNγ enzyme-linked immunosorbent spot (IFNγ ELISpot) assay according to the
manufacturer’s recommendations (R&D Systems, Minneapolis, MN). Wells were seeded with 2.5 x 105
PBMCs and stimulated with pooled peptides at 10 µg/mL, whole H1N1pdm09 virus (WV) at a
multiplicity of infection (MOI) of 0.5, pokeweed mitogen (PWM) at 1 µg/mL, or culture media in a
final volume of 0.25 mL.
Immune responses to the IAV epitopes contained in the vaccines were evaluated using PBMC
from each of 32 study animals. To simplify the analysis, four pools of peptides were evaluated at all
PBMC sampling points – one that included all 48 predicted peptides (All); a second pool that contained
26 class I and II peptides predicted from internal proteins (Int); a third pool that contained 8 class II
peptides predicted from external proteins (Ext-II); and a final pool that contained 14 class I peptides
predicted from internal proteins (Int-I) (Fig. 2).
In addition to the assays that were performed using pooled peptides, we evaluated epitopespecific IFNγ responses to individual peptides at 49 dpv, using PBMC from pigs in groups PigMatrixEDV and FluSure (five from each group). Triplicate assays were performed for all peptide stimulations
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and for controls. After 18 h of incubation in a 37°C humidified 5% CO2 incubator, the ELISpot plates
were washed and developed according to the manufacturer’s recommendations. The ELISpot plates
were then scanned in a CTL-ImmunoSpot S5 UV analyzer and spot counts were recorded using the
ImmunoSpot software (Cellular Technology Ltd., Shaker Heights, OH). Results were recorded as the
average number of spot forming cells (SFC) over background and adjusted to spots per 106 PBMCs. A
response was considered positive if the number of spots was greater than or equal to 20 SFC over
background per 106 PBMC.
At the end of the study, pigs were SLA-typed using a low-resolution group-specific typing
method [31] to evaluate SLA diversity and correlate epitope predictions with IFNγ responses. Select
pigs were typed: two pigs from group NV, eight from Sham, seven from PigMatrix-EDV, seven from
FluSure.
Retrospective analysis
IFNγ responses to individual peptides were compared to predictions using cohort-specific class I and II
SLA PigMatrices. Class I peptides were scored and considered potential binders if the mean of
significant Z-scores was above 1.64. Class II peptides with cluster scores above 10 were categorized as
potential ligands. Experimentally, peptides that induced more than 20 SFC over background per 106
PBMCs in at least one pig were considered positives. Based on the comparison of experimental results
and predictions, peptides were divided into one of four categories (true positives, true negatives, false
positives, and false negatives). True-positive peptides were predicted and validated in vitro as
immunogenic, while true-negative peptides were predicted and biologically validated to be nonimmunogenic. False negative peptides were predicted to be non-immunogenic, yet produced a positive
response; false positive peptides were predicted to be immunogenic, but produced no response in the
IFNγ ELISpot assay. To evaluate the predictive performance of the matrices, we calculated the positive
and negative predictive values (PPV and NPV, respectively) and area under the receiver operating
characteristic (ROC) curve (AUC) using the sensitivity and 1 - specificity (false positive rate) values.
Antibody evaluation
Pig serum was collected at 0 and 42 dpv for hemagglutination inhibition (HI) assay to assess antibody
responses following vaccination as described previously [43]. Briefly, sera were heat-inactivated at
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56°C for 30 min and then treated with a 20% suspension of kaolin (Sigma-Aldrich, St. Louis, MO) and
subjected to adsorption with 0.5% turkey red blood cells (RBC) to remove nonspecific hemagglutinin
inhibitors and natural serum agglutinins. The HI assays were then performed using H1N1pdm09 and
OH/07 (γ-cluster H1) strains as antigen. Titers were determined using two-fold serial dilutions to detect
the reciprocal endpoint of HI, log2 transformed and reported as the average geometric mean reciprocal
titer for each group. Sera with titers <40 were considered HI negative or suspect.
Statistical analysis
IFNγ responses to restimulation treatments (pooled peptides and WV) in the PigMatrix-EDV group and
the FluSure group, measured at 42, 49 and 63 dpv, were compared using a Kruskall-Wallis test
followed by side by side comparisons of the groups using Dunn’s correction for multiple comparisons.
The same test was used for comparison of HI antibody titers between groups at 42 dpv. Wilcoxon
matched-pairs test was used to compare IFNγ responses within groups. To evaluate IFNγ responses to
more than two restimulation treatments for a group at a specific timepoint and the effect of the boosts in
the PigMatrix-EDV group, the Friedman test using Dunn’s correction was used. P values of less than
0.05 were considered significant. All the statistical analyses were performed using GraphPad Prism
software (GraphPad, San Diego, CA).

Results
Epitope selection
A total of 28 class I and 20 class II peptides were down-selected for inclusion in the prototype
PigMatrix-EDV IAV vaccine (Fig. 3), following immunoinformatic predictions. Peptides were selected
based on predicted binding to class I (SLA-1*0101, 1*0401, 2*0101, and 2*0401) and class II (SLADRB1*0101, 0201, 0401, and 0601) SLA alleles.
Since external proteins (HA and NA) are highly variable, it was difficult to identify highly
conserved potential epitopes. For this study, the minimum IAV strain coverage required for epitopes
derived from HA and NA proteins was 25%. We selected epitopes to achieve the broadest possible
coverage despite this constraint. In contrast, internal proteins are conserved due to the presence of the
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TRIG cassette; therefore, the coverage threshold for peptides selected from internal proteins (M1, M2,
NP, NS1, NS2, PA, PB1, PB1-F2, PB2) was 85%.
Fourteen class I peptides were selected from external proteins and 14 peptides were selected
from internal proteins. The mean Z-score of class I peptides was 2.87(1.03), [reported as mean(standard
deviation)]; these are high-scoring peptides that are considered likely to be T cell epitopes. Twenty-four
of the class I peptides (85.7%) were predicted to bind to four alleles. Eleven of the 14 class I peptides
(78.6%) identified in the external proteins were >85% identical in at least three of seven IAV strains.
Similar epitopes were selected to evaluate strain specificity; HA_1 and HA_2 differed by one amino
acid, but HA_1 was 100% identical in four strains, whereas HA_2 was present only in one IAV
(OH/07). NA_14 was identified in one IAV, but its sequence was 77.8% identical (7 of 9 amino acids)
to NA_11, which was conserved in two other IAVs. Both peptides were predicted to bind to four class I
SLA alleles. For the putative class I peptides derived from internal proteins, 11 of 14 (78.6%) were
100% identical in the IAVs analyzed.
Cluster scores for all the selected class II ICS were greater than 10. Eight of the 20 ICS were
derived from external and 12 from internal proteins. Their lengths ranged from 16 to 25 amino acids.
All the peptides had at least one 9-mer frame predicted to bind to at least three SLA class II alleles;
80% (16 of 20 peptides) had at least one 9-mer predicted to bind to all four SLA class II alleles. From
the external proteins, five of the predicted peptides were >85% identical in at least three IAV strains.
Class II peptides derived from internal proteins were >85% identical in all seven IAVs, with exception
of M_10 that had 84.2% identity (differed by 3 amino acids) with its counterpart in OH/04. Taken
altogether, the immunoinformatics-predicted sequences represent a set of potentially broadly reactive
swine influenza T cell epitopes.
Epitope-driven DNA vaccine construction
As a tool to evaluate epitope-specific responses to predicted peptides, we designed two prototype DNA
vaccines; one containing class I-restricted epitopes and one containing class II-restricted epitopes
(Supplemental Text 1). To minimize potential junctional immunogenicity of the class I construct,
breakers (‘AAY’) were inserted at seven of 27 peptide junctions. In one case, a ‘spacers’ (‘GPGPG’)
was introduced into the class II construct to disrupt the formation of junctional epitopes. Both
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constructs were designed to avoid potential transmembrane domains. The DNA vaccine vectors also
contained signal sequences to target the string of epitopes to the proteasome or the secretory pathway.
These signal sequences, UbA76 for class I and TPA for class II, were of human origin; however,
BLAST analysis showed that amino acid sequences from both were 99% and 71% identical,
respectively, to their swine counterparts.
T cell immunogenicity
Epitope-specific responses to pooled PigMatrix-predicted peptides were demonstrated in immune recall
IFNγ ELISpot assays using PBMC isolated at 42 (day of second boost), 49, and 63 dpv from animals in
the PigMatrix-EDV and Sham groups (Fig. 4A). The four peptide pools (All, Int, Ext-II, and Int-I; Fig.
2) used for restimulation induced statistically significant different responses between pigs vaccinated
with PigMatrix-EDV and Sham (p<0.05). IFNγ responses measured in pigs from PigMatrix-EDV and
FluSure groups were significatively different (p<0.05), with exception of restimulation with pool Ext-II.
No significant differences were observed between pigs vaccinated with FluSure and Sham. In
PigMatrix-EDV-vaccinated pigs, we expected class II epitopes to dominate in the immune response to
external proteins, and class I epitopes to dominate the immune response to the internal proteins.
Contrary to our expectation, the number of IFNγ SFC induced by pools of class II peptides from
external proteins (Ext-II) and class I peptides from internal proteins (Int-I) was below 20, which was
significantly lower (p<0.001) than responses to all peptides pooled together (All) and peptides derived
from internal proteins (Int). SFC were not statistically different between All and Int pools (p=0.74).
These results suggest that immune responses to class II predicted epitopes contained in internal IAV
proteins dominate the PigMatrix-EDV-induced response.
IFNγ SFC induced by restimulation with WV in PBMC from pigs in the PigMatrix-EDV group
were also statistically different from Sham (p<0.05) at all three measured time points. This result
suggests that T cells raised against epitopes contained in the prototype DNA vaccine recognize epitopes
presented in whole virus stimulation in vitro.
It is interesting to note that the IFNγ SFC induced by restimulation with All and Int pools were
not statistically different from responses to WV in PBMC from the PigMatrix-EDV group, with the
exception of responses at 49 dpv (All: 49 (32.34), Int: 43.57 (33.93), WV: 84.29 (47.92) SFC per 106
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PBMC; p=0.02; Fig. 4A). This may suggest that the epitopes in the peptide pools were recognized by T
cells that were responsible for the majority of T cell responses to WV, in vitro. Differences in the
antigen presentation processes (in vitro) for WV and peptides may explain the differences at 49 dpv
[44]. Alternatively, WV RNA could have played a role in the expansion of T cell responses in vitro
[45]. It is also possible that the IFNγ ELISpot assay only sampled a fraction of the antigen-specific cells
present in the PBMC after in vitro stimulation; thus, technical limitations may explain comparable
responses between pooled peptides and WV restimulation.
Interestingly, IFNγ responses to WV restimulation did not significantly differ in PigMatrixEDV (73.84 (54.48)) and FluSure-immunized (127.55 (175.86)) pigs (Fig. 4A). Note that the mean and
high variability in the FluSure group was due to consistently high recall responses in PBMC from one
“high responder pig” (FS-442; Fig. 4A, marked with +) at the three time points tested (mean IFNγ SFC
per 106 PBMC excluding this pig was 58.52 (51)). Thus, the epitope-based vaccine elicited consistent
IFNγ responses equivalent to those induced by a tetravalent commercial WIV vaccine.
Boost immunizations in the PigMatrix-EDV group did not result in significant changes in the
number of IFNγ SFC when PBMCs were restimulated with All, Int pools and WV (Fig. 4A and
enhanced in Fig. 4B).
Restimulation with individual peptides
As noted before, we suspected that recall response to peptide pools in PBMC from PigMatrix-EDV
vaccinated pigs was primarily driven by class II predicted epitopes derived from internal IAV proteins.
This observation was confirmed by evaluating IFNγ responses to individual peptides a week after the
second boost (49 dpv) (Fig. 4C and 4D). PBMC from pigs immunized with PigMatrix-EDV or FluSure
(five from each group) were restimulated with individual class I and II peptides. Four class I peptides
(derived from external proteins) and seven class II peptides (derived from internal proteins) induced
more than 20 IFNγ SFC per 106 PBMC over background for at least one pig immunized with PigMatrixEDV. At 49 dpv, none of the peptides induced significant responses in PBMC from the five FluSurevaccinated pigs tested. Note that the high responder pig from the FluSure group, who registered the
highest responses to peptide pool restimulation at 42, 49, and 63 dpv (FS-442, Fig. 4A, marked with +),
was not included in the individual peptide restimulation assays.
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Retrospective analysis using cohort-specific predictive matrices
Putative epitopes were predicted for binding to a set of SLA alleles prevalent in outbred swine
populations [31,32]. To determine if those alleles were expressed in the study cohort, SLA types were
determined at low resolution [31,32] at the end of the study for eight pigs from the Sham group, seven
from PigMatrix-EDV, seven from FluSure, and two from NV group (Supplemental Table 2). By
chance, none of the SLA-typed pigs tested in individual peptide ELISpot assays (Table 1), expressed
any of the alleles used for epitope predictions. A pig that responded to four class I peptides (PigMatrixEDV-427) was not SLA-typed; thus, no correlation of immune recall and epitope predictions could be
made between the existing matrices and these ELISpot data.
To retrospectively evaluate the IFNγ responses to individual peptides and the association with
specific SLA haplotypes, we developed class I and II matrices specific for the most frequent SLA-1,
SLA-2, and SLA-DRB1 alleles expressed in the actual cohort (cohort-specific, Table 1). Although
certain low-resolution results were ambiguous, we can make some assumptions based on common
associations. For SLA class II, based on common association with DQB1 and DQA alleles [32], we
expect that SLA-DRB1*0401-02 is likely to be DRB1*0402 and DRB1*06XX is likely to be
DRB1*0602. These two alleles were expressed in 79% of the typed pigs. For the rest of the frequently
expressed alleles, we developed XX01 as the default matrix (e.g. for DRB1*07XX, we developed SLADRB1*0701 prediction matrix). Thus, we developed cohort-specific prediction matrices for SLA1*0801, 1*1201, 1*1301, 2*0501, 2*1201, DRB1*0402, 0602, 0701, and 1001.
The initial set of peptides was selected because they were predicted to bind promiscuously to
the SLA alleles that are prevalent in outbred swine populations (SLA-1*0101, 1*0401, 2*0101, 2*0401,
DRB1*0101, 0201, 0401, and 0601). However, a reduced number of peptides were predicted to bind to
the actual, cohort-specific alleles, once this information was available (Fig. 5). For example, none of the
peptides were predicted to bind the most frequently expressed SLA allele for this cohort (SLA-1*0801).
Cohort-specific predictions yielded a total number of hits per allele, for this set of peptides, that was
41.7% lower than the initial prediction based on reported prevalent alleles. Despite the fact that the
predictions did not correspond well with the sampled SLA, 23 PigMatrix-EDV peptides were still
predicted to bind to alleles in the cohort, explaining the responses observed in the pool restimulation.
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This also suggests that initial predicted promiscuity (i.e. ability for a peptide to bind to multiple alleles)
present in selected peptides extends to additional cohort-specific alleles.
Cohort-specific class I predictions
Further evaluation of the cohort-specific predictions revealed that PigMatrix predictions for the 28 class
I peptides (Fig. 5, top) had high sensitivity (1.0) and NPV (1.0), and moderate specificity (0.63).
Cohort-specific prediction correctly classified 15 of the 24 peptides that were non-immunogenic. In
terms of immunogenic peptides, four out of four were predicted as immunogenic, though nine false
positive peptides were also observed, contributing to the low PPV (0.31).
To evaluate the predictive performance of the cohort-specific prediction, we built an ROC
curve and then calculated the AUC (a value of 1 corresponds to a perfect prediction and 0.5 to a random
prediction). The AUC was 0.81, which shows that predictions for cohort-specific alleles had high
predictive power. However, the size of the dataset may have influenced these results; prospective
studies on larger cohorts of pigs would be required to validate this observation.
Cohort-specific class II predictions
Predictions targeting cohort-specific SLA alleles showed that peptides had limited binding likelihood.
Cohort-specific cluster scores were lower for 18 out of 20 peptides compared to cluster scores for SLA
alleles reported as prevalent in outbred pigs (SLA-DRB1*0101, 0201, 0401, 0601; Fig. 5, bottom).
Note that the cohort-specific cluster score of false negative peptide M_10, which calculated for four
SLA-DRB1 alleles (DRB1*0402, 0602, 0701, and 1001), was below 10 (the threshold we set for
potential binders), but it was still predicted to bind to the two SLA-DRB1 alleles (DRB1*0602 and
1001) expressed by PigMatrix-EDV SLA-typed pigs (pig PigMatrix-EDV-432 only expressed SLADRB1*1001), and corresponded to the positive responses observed.
Cohort-specific class II predictions (Fig. 5, bottom) had high sensitivity (0.86) and NPV (0.90),
and moderate specificity (0.69) and PPV (0.60). They also showed high predictive power (AUC 0.77)
for the set of 20 class II peptides. Nine of the 13 peptides that were non-immunogenic were correctly
predicted and six out of seven immunogenic peptides were predicted as immunogenic. Only four
peptides that were predicted to be immunogenic were non-immunogenic in T cell assays.
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Overall, the retrospective analysis of 48 peptides using predictions for cohort-specific SLA
alleles showed high sensitivity, moderate-to-high specificity and high predictive power for both class I
and II SLA alleles. Predictions were particularly effective identifying non-immunogenic peptides as
demonstrated by their high NPVs. Cohort-specific predictions correctly identified 24 out 37 nonimmunogenic peptides and 10 out of 11 positive peptides. Still, it is important to mention that the
limited number of peptides makes these results less robust. A larger dataset of peptides will be required
to confirm the predictive power of the matrices.
Antibody responses
FluSureXP® induced detectable HI antibody against OH/07 γ-cluster virus, with no cross-reactivity to
the H1N1pdm09 virus with serum collected 42 dpv (Table 2). HI antibody titers against OH/07 were
significantly different from Sham and PigMatrix-EDV (p<0.001). PigMatrix-EDV did not induce a
detectable positive HI antibody response against H1N1pdm09 or OH/07 at 42 dpv, which is not
surprising, as the T cell epitopes were not expected to encode B cell epitopes.

Discussion
In this study, PigMatrix, an immunoinformatics tool for predicting swine T cell epitopes, was used to
identify class I and II epitopes highly conserved among seven IAV strains representative of those
prevalent in U.S. swine. To evaluate the immunogenic potential of the predicted peptides, IFNγ SFC
recall responses were measured in pigs vaccinated intramuscularly with prototype DNA vaccines
(PigMatrix-EDV) encoding strings of class I and II epitopes or a commercially available swine IAV
vaccine. Recall responses induced by pooled peptides in PBMCs isolated from pigs vaccinated with
PigMatrix-EDV were significantly greater than responses in pigs vaccinated with empty plasmids.
Furthermore, PigMatrix-EDV-vaccinated pigs responded to WV (H1N1pdm09) restimulation, showing
that the epitope-based immunization gave rise to T cells that are cross-reactive with epitopes present in
the whole virus in vitro. In addition, overall responses to WV restimulation were comparable to those
induced by All and Int pools. Moreover, epitope-specific recall responses to WV in pigs immunized
with a prototype epitope-based vaccine were similar to responses in pigs immunized with the
commercial vaccine.
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A challenge study was conducted to evaluate protective efficacy of PigMatrix-EDV. Pigs were
intranasally challenged with H1N1pdm09 virus, but due to age at challenge and route of challenge,
pathology and viral load in non-vaccinates was limited, so assessing protection overall in vaccinates
was also limited. There was no evidence of enhanced lesions (VAERD) in vaccinates, and outcome in
DNA-vaccinates and FluSure vaccinates was similar (data not shown). Future work aimed at assessing
efficacy of the DNA approach is warranted, and further consideration will need to be given to animal
age, route of challenge, challenge strain, and SLA haplotype of animals to adequately evaluate the
vaccine. Ideally, a group of pigs challenged with influenza A virus should be included to evaluate
whether the predicted T cell epitopes are also induced during natural infection.
Our initial set of alleles used for T cell epitope prediction did not correspond well with the
cohort ultimately selected. For this prospective study, we developed predictions for SLA alleles that had
been reported to be frequently expressed in outbred swine populations [31,32]. However, post hoc SLA
typing results showed that those alleles were not prevalent in pigs in the study. Still, some peptides
induced IFNγ SFC responses, demonstrating the initial set of alleles positively predicted promiscuous
epitopes. This has significant implications for vaccine design because identification of epitopes capable
of binding to multiple SLA alleles limits the number of epitopes required to cover an SLA diverse
population. A retrospective analysis using cohort-specific alleles showed that some of the peptides were
predicted to bind to the new SLA alleles, although the set of peptides overall was not optimally matched
to the cohort. These results indicate that selecting epitopes for promiscuity, when pig SLA-typing is not
available, may be relevant because conservation of binding likelihood in a promiscuous epitope may
extend to additional (untested) alleles. While it is clear that we will need to expand the set of alleles for
future vaccine designs, this finding suggests that using immunoinformatics tools to identify
promiscuous T cell epitopes can contribute to those future designs [26,46].
Designing epitope-based vaccines for pigs is hindered by the lack of information on SLA
diversity in the U.S. swine population. A systematic evaluation of the SLA frequency will make it
possible to develop and apply predictions for the most representative SLA alleles (supertypes) [47,48]
to vaccine designs that cover a high percentage of the swine population. In addition, a more streamlined
(i.e. rapid, high resolution, commercially available) approach to SLA typing would significantly
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improve the ability to study T cell responses to influenza and other economically important diseases
such as porcine reproductive and respiratory syndrome (PRRS) and porcine epidemic diarrhea (PED).
In this study, class II peptides from internal proteins were highly conserved (identity >85%)
across all the analyzed strains and were shown to be the most immunogenic. Internal proteins from IAV
are conserved across multiple strains because of the prevalence of two evolutionary lineages, H1pdm09
and TRIG, in the U.S. swine population [33]. We note that the genome sequences of the strains in the
commercial vaccine are not available; however, it is likely that the internal epitopes were from the
TRIG cassette (all seed strains predate introduction of H1N1pdm09 into the swine population). For this
reason, it was interesting to see that PBMC from pigs immunized with FluSure had more limited IFNγ
SFC responses to peptide pools, even though the pigs expressed similar SLA alleles to pigs in the
PigMatrix-EDV group. This observation supports the hypothesis that epitope-based vaccines promote
more efficient processing and presentation of their own epitopes as compared to whole-protein-based
vaccines. Similar results were observed in mouse studies using T cell epitope-based DNA vaccines for
H. pylori, where 33 out of 50 peptides stimulated more than 50 IFNγ SFC in splenocytes from the group
vaccinated with an epitope-based DNA vaccine, but only two of the peptides were recognized in the
group vaccinated with the whole bacteria lysate [49]. If epitope-based vaccines are able to induce
immune responses to more individual epitopes than whole pathogen formulations containing the same
epitopes, selection of the right epitopes, with the right breadth of SLA coverage, may lead to the
development of more efficacious vaccines than currently exist [49].
Contrary to our expectations, we observed that IFNγ recall responses to class I peptides were
restricted to external proteins, while responses to class II peptides were focused on epitopes derived
from internal proteins. In human studies, most cross-reactive CD8+ (class I) and CD4+ (class II) T cell
epitopes are derived from internal IAV proteins [14,50]. Compared to class I epitopes derived from
internal proteins, HA- and NA-specific class I epitopes are said to be rare [51], but a few SLA-restricted
HA and NA class I peptides have been reported [36,52]. In this study, the four class I peptides that
induced IFNγ responses were derived from HA and NA. Sequence alignments using BLAST
demonstrated that these peptides are conserved in different swine IAV strains. In humans, class II
epitopes derived from HA and NA have also been reported [14,22,53], but none of the potential
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epitopes from these antigens predicted by PigMatrix elicited measurable responses in the PigMatrixEDV group (Fig. 4D). The seven class II peptides recognized by PBMC in this study were derived from
internal proteins (M, NP, PA, and PB). Similar to class I peptides, these peptides are conserved in IAVs.
Previous studies have shown that cross-reactive T cell responses to conserved epitopes may provide
broader protection against diverse strains than antibodies that target variable antigens [15,22].
We searched the Immune Epitope Database (www.iedb.org) for swine influenza T cell epitopes
and found that substrings of the predicted class II peptides NP_1, PA_7, PB_8, and M_12 have been
reported to induce positive T cell responses, as measured by different methods (e.g. IFNγ ELISpot,
tetramer staining, intracellular cytokine staining), for at least one human MHC class II allele. The
published epitopes were derived from H1N1, H5N1, and H2N2 IAV strains. Thus epitopes that induce
T cell responses in both human and pigs can be identified. Additionally, these epitopes may contribute
to heterosubtypic cell-mediated responses against zoonotic IAV.
We did not expect that the epitope-based vaccine would induce antibodies, and indeed,
PigMatrix-EDV did not induce HI antibodies that reacted to OH/07 or H1N1pdm09. While the
commercial vaccine induced antibodies against OH/07, they did not cross-react with H1N1pdm09. The
commercial vaccine contains four IAV strains (H1γ, H1δ1, H1δ2 H1N1 viruses, and one cluster IV
H3N2 virus). OH/07 is an H1γ virus, which explains the positive HI response to this virus.
In conclusion, observed epitope-specific IFNγ recall responses demonstrate the potential for
PigMatrix to predict conserved, promiscuous and immunogenic T cell epitopes. Further studies will
evaluate the utility of PigMatrix for designing epitope-driven vaccines for swine. Epitope-driven T cell
responses may not fully prevent IAV infection, but could reduce viral burden, as was observed for the
2009 H1N1 outbreak [22]. Rapid viral clearance and lower morbidity are important objectives for swine
IAV vaccines, since current vaccines do not provide complete protection against variant strains.
Moreover, epitope prediction tools could be used to assess the potential for existing commercial vaccine
strains to protect against newly emergent strains of IAV. Improved immunoinformatics tools that target
a comprehensive set of SLA alleles may contribute to the development of vaccines against other
prominent swine diseases and provide a significant positive impact for pig health and swine producers.
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Table 1. Low resolution SLA-type alleles of pigs tested in individual peptide ELISpot assays.
SLA class Ia

SLA class IIa

Group

Pig

SLA-1

SLA-2

DRB1

PigMatrix-EDV

429

08XX,12XX,1301

0901-02,12XX

06XX,10XX

431

08XX,12XX,1301

05XX,10XX

06XX,10XX

432

08XX

05XX,10XX

10XX

433

08XX,12XX,1301

0901-02,12XX

06XX,10XX

435

1103,12XX,1301

10XX,jh02

06XX

436

08XX

05XX,12XX

0401-02,10XX

437

12XX,1301

10XX

06XX

439

08XX

12XX

0401-02

441

1103,12XX,1301

10XX,jh02

06XX

FS

a

Only loci for which prediction matrices were developed are shown.

Table 2. Geometric mean reciprocal titers of HI antibodies to different virus in sera collected at
42 dpv.
Viral antigen*
Vaccine group

H1pdm09

OH/07

NV

7

6

Sham

6

6

PigMatrix-EDV

10

6

FluSure

8

104

*Titers <40 are considered negative or suspect.
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Fig. 1. Experimental outline.

Fig. 2. Peptide pools tested.All: 48 peptides. Int: 26 class I and II peptides predicted from internal
proteins. Ext-II: Eight class II peptides predicted from external proteins. Int-I: 14 class I peptides
predicted from internal proteins.
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Fig. 3. Class I and II predicted peptides. Peptides were selected based on predicted binding to class I
and class II SLA alleles and conservation in IAV strains. The identity percentage between peptides and
IAV strains is shown (100% dark gray, 99% - 85% gray, and <85% white). The Peptide ID is coded to
the source protein. Sequences not available are marked with -.
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Fig. 4. Peptide immunogenicity measured by IFNγ ELISpot. (A) PBMC (2.5 x 105) isolated at three
different time points (42, 49, and 63 dpv) from pigs immunized with empty plasmid (Sham), epitopedriven DNA vaccine (PigMatrix-EDV) and commercial vaccine (FluSure) were restimulated with
pooled peptides (All, Int, Ext-II, and Int-I) at 10 µg/mL and whole virus (WV). The number of epitopespecific IFNγ spot forming cells (SFC) induced by the pools were measured using ELISpot assays.
“High responder pig” (FS-442) is marked with +. (B) To evaluate vaccine boost effect, IFNγ responses
to pooled peptides were measured at three different time points. For A and B, SFC over background,
adjusted to spots per 106 of PBMC seeded, are represented with bars indicating means and error bars
indicating standard deviation (SD). Pooled peptide responses showing statistical significance when
compared to Sham are indicated: **p<0.01, *p<0.05. Significant statistical difference for PigMatrixEDV between restimulations at 49 dpv is also shown. Same colors and shapes are used in both figures.
(C) PBMC from pigs vaccinated with PigMatrix-EDV and FluSure were restimulated with individual
class I peptides and (D) class II peptides one week after the second boost (49 dpv). For C and D, SFC
over background per 106 PBMC are shown. A response was considered positive if the number of spots
was greater than or equal to 20 SFC over background per 106 PBMCs (dashed line).
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Fig. 5. Comparison between prediction for prevalent and cohort-specific SLA alleles. Peptides
were predicted to bind to a set of previously reported class I and class II SLA alleles prevalent in the
U.S. swine population (prevalent). Based on low-resolution SLA-typing results, those alleles were not
represented in the studied pigs. Prediction matrices were developed to predict binding potential of
peptides to the most frequent SLA alleles found in the cohort (cohort-specific). (Top) Mean of
significant Z-scores (above 1.64) over prevalent class I SLA alleles (SLA-1*0101, 1*0401, 2*0101, and
2*0401) and cohort-specific (SLA-1*0801, 1*1201, 1*1301, 2*0501, and 2*1201) are shown for each
peptide. Peptides with a mean of significant Z-scores above 1.64 (dashed line) are considered potential
binders. (Bottom) Cluster scores calculated for prevalent class II SLA alleles (DRB1*0101, 0201, 0401,
and 0601) and cohort-specific alleles (DRB1*0402, 0602, 0701, and 1001) are shown for each peptide.
Cluster scores above 10 (dashed line) are considered as potential binders. Based on the retrospective
evaluation, peptides were classified in four categories (TN: true negatives, TP: true positives, FN: false
negatives, and FP: false positives). AUC, Sensitivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV) are shown.
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Abstract
Background: Hemagglutinin (HA) is the most variable antigen of swine influenza A viruses (IAV) and
the major target of protective antibody responses; hemagglutination inhibition (HI) antibody titers are
widely used to predict vaccine cross-protection. T cell epitopes that are cross-conserved between IAV
strains also play a role in protection.
Objective: Determine the association of T cell immunogenic potential with vaccine-induced protection.
Methods: We developed a method for T cell epitope content comparison (EpiCC) and used it to
compare field H1 swine IAV HAs to HAs in a commercial vaccine. The PigMatrix algorithm was used
to predict T cell epitope content for twenty-three HA sequences representing the major H1 swine IAV
phylo-clusters. The T cell epitope-based relatedness (EpiCC scores) between vaccine and field viruses
was calculated and compared to experimental data from previous efficacy studies where immunization
induced protection in the absence of cross-reactive HI antibodies.
Results: A comparison of HA T cell epitope content of the γ-cluster H1 vaccine virus to viruses used in
homosubtypic challenge studies yielded a relatedness score associated with protection, assuming
minimal epitope variation of other viral antigens.
Conclusion: The T cell epitope content relationship deduced from vaccine efficacy studies evaluated
here may support the hypothesis that T cells contribute to vaccine efficacy. EpiCC could be used
retrospectively and prospectively to estimate the immunologic relationship of genetically and
antigenically variable viruses assessed in vaccine efficacy studies. EpiCC may complement studies of
HI cross-reactivity and phylogenetic data for the prospective selection of influenza strains in flu vaccine
development. Complete viral proteome EpiCC analysis would provide more comprehensive information
to estimate vaccine efficacy.

Keywords: Computational immunology, hemagglutinin, SLA, swine influenza H1 viruses, vaccine
efficacy, T cell epitope content comparison, T cell epitope prediction.
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Introduction
Influenza A viruses (IAVs) cause a highly contagious respiratory disease in swine that has a significant
economic impact on the pork industry [1]. Hemagglutinin (HA) and neuraminidase (NA) are the two
major surface glycoproteins that define IAV subtypes and play a key role in antigenicity, pathogenesis,
host range, and diagnosis. The segmented IAV genome allows for antigenic shift by reassortment of
RNA segments from different viral strains infecting the same cell, generating novel viruses [2].
Antigenic drift due to accumulation of mutations in HA and NA also contributes to the remarkable
diversity of IAVs [2].
Currently, H1N1, H1N2 and H3N2 are the predominant IAV subtypes co-circulating in the
North American swine population. These subtypes are further subdivided based on the genetic and
antigenic properties of HA. For H1 viruses, seven distinct genetic phylo-clusters (α, β, γ, γ-2, δ1, δ2 and
pandemic (pdm09)), have been identified [3]. The HA gene of α, β γ, and pdm09 cluster viruses is most
similar to classical swine H1N1 (cH1N1) [3]. HA from human-origin δ viruses can be differentiated in
two subclusters, δ1 and δ2 [4]. Based on the antigenic properties of HA, serological cross-reactivity
between H1 clusters similar to cH1N1, can be variable, but there is limited to no cross-reactivity
between these viruses and the even more divergent δ cluster viruses [3,5]. This diversity presents a
challenge to pork producers, veterinarians and vaccine manufacturers who wish to match vaccine
strains to relevant field strains.
Most of the North American commercial vaccines against swine IAV contain inactivated
viruses. The predominant antibody responses induced by these vaccines is to the HA proteins [1,6].
Therefore, hemagglutination-inhibiting (HI) antibody titers as well as genetic information of HAs are
used to evaluate the potential for one vaccine to protect against variant strains [6]. However, based on
lung lesions and viral titers, full or partial protection of pigs can be observed following vaccination with
inactivated commercial vaccines, in the absence of antibody cross-reactivity [1,6–12].
Protection in the absence of neutralizing antibodies is presumed to be due to cell-mediated
immunity (CMI) to cross-conserved T cell epitopes [13,14]. Cross-conserved T cell epitopes have been
associated with protection against influenza in other contexts. For example, in humans, immunity to
cross-conserved epitopes during the 2009 H1N1 IAV pandemic may have contributed to attenuation of
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morbidity in some age groups [13,15]. In a previous study, we showed that a DNA vaccine based on
eight HA T cell epitopes and one NA epitope conserved between seasonal and pdm09 lowered lung
viral loads in HLA-DR3 transgenic mice challenged with pdm09 [16]. Cross-protection induced by
conserved antigens does not induce complete protection against infection, but reduces mortality,
morbidity, virus replication, and viral shedding [17,18]. CMI depends on the activation of cytotoxic T
lymphocytes (CTL, CD8) and T helper (Th, CD4) lymphocytes when their T cell receptors (TCR)
recognize T cell epitopes presented by class I or class II major histocompatibility complex (MHC)
molecules on the surface of antigen presenting cells or infected cells [19]. CTL kill virus-infected cells,
whereas Th responses support memory CD8 T cell development and provide help to B cells for highaffinity, neutralizing antibody responses [13].
Here, we describe an approach for T cell epitope content comparison (EpiCC) that compares
putative class I and II epitopes to assess relatedness across antigens and predict potential vaccine
efficacy. Using this method, we evaluated whether T cell epitope relatedness could explain protection
against heterologous IAV challenge (in the absence of cross-reactive antibodies). EpiCC uses
PigMatrix, an algorithm that predicts class I and II T cell epitopes specific to swine MHC (Swine
Leukocyte Antigen, SLA) alleles [20]. PigMatrix and additional tools in the iVAX toolkit [21] have
been used to prospectively identify conserved T cell epitopes from different H1 phylo-clusters [21,22].
We applied PigMatrix and EpiCC to HA proteins from 23 swine IAV strains representing the major H1
phylo-clusters circulating in the North American swine population. Since the internal genes in North
American swine influenza have remained prevalent and conserved since 1998 (due to the emergence of
the triple reassortant internal gene (TRIG) cassette), we assumed minimal T cell epitope differences
therein and focused on the critical and most variable swine IAV antigen, HA [3,23,24]. Comparing the
results of vaccine efficacy studies with the IAV EpiCC scores, we identified a level of T cell epitope
related for a γ-cluster H1 vaccine virus associated with protection.
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Methods
Sequences
HA sequences from 23 H1 IAV strains were included in the analysis (Table 1). Twenty sequences were
from swine H1 viruses representing α, β, γ, γ-2, δ1, δ2 and pdm09 phylo-clusters and three were from
the H1 vaccine viruses (γ, δ1 and δ2 H1 phylo-clusters) in FluSure XP® (FS; Zoetis Inc, Florham Park,
NJ). Phylogenetic analysis was performed using MEGA 7 [25]. HA nucleotide sequences were aligned
with MUSCLE and an evolutionary tree was inferred using the Maximum likelihood method with 500
bootstrap replicates.
MHC binding prediction
The HA amino acid sequences of the 23 IAV strains were screened using PigMatrix [20]. PigMatrix
parses sequences into 9-mers and assesses the binding potential of each 9-mer i to SLA class I and II
alleles. For each individual allele a in a set of MHC alleles A, PigMatrix raw scores r are normalized to
Z-scores using the average µ and the standard deviation σ of scores calculated for 100 000 random 9mers.
!(!)! =

!−!
!

In this normalized set of scores for each SLA allele, 9-mers with Z-scores above 1.64 comprise the top
5% of sequences with significant SLA binding potential. Increasing Z-scores correlate with higher
MHC binding probability.
The distribution of SLA alleles among pig herds in the United States is unknown. Binding was
therefore predicted to a set of SLA class I and II alleles that were frequently expressed in a cohort tested
in a previous study (SLA-I: SLA-1*0801, 1*1201, 1*1301, 2*0501, 2*1201, 3*0501, 3*0601, and
3*0701; SLA-II: SLA-DRB1*0201, 0402, 0602, 0701, and 1001) [22].
Since data are lacking on breadth of coverage for SLA, a comparison was performed using
HLA alleles. The breadth of coverage of HLA alleles (i.e. the ability to cover a global population) is
known [26,27]; therefore, the HLA-restricted T cell epitopes that could be identified in these IAV
sequences was quantified and compared to the epitopes uncovered in the sets of SLA alleles. The
following HLA class I and class II supertype alleles were used for this comparison, HLA-I: A*0101,
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A*0201, A*0301, A*2402, B*0702, and B*4403, and HLA-II: DRB1*0101, 0301, 0401, 0701, 1101,
1301, and 1501 [28].
T cell epitope content comparison
The EpiCC algorithm assesses the relatedness of a protein sequence of a strain s and a protein sequence
of a vaccine strain v based on a comparison of their T cell epitope content, predicted for the same set of
MHC alleles A. For any comparison, the predicted epitope content can be either shared between
sequences or unique to the strain or to the vaccine. Thus, the score of the comparison between the
epitope content of s and v (EpiCC score or T cell epitope-based relatedness) considers scores of shared
and unique epitopes (Fig. 1).
Intuitively, the epitope content of a protein depends on its epitope density. So, if a ‘high
epitope density’ protein is compared to a highly similar protein and many of their epitopes are
conserved or shared between the two strains, the scores of shared epitopes will be high; consequently,
the score of the comparison of their epitope content (EpiCC score) will also be high. The score will be
even higher if the 9-mer epitopes are predicted to bind with high probabilities to alleles in the set A.
We hypothesized that if epitopes in a vaccine match the epitopes in the challenge strain, and
vaccine and strain unique epitopes are rare, the memory T cells induced by the vaccine are likely to
cross-react with epitopes from the challenge strain. The model assumes (1) a naive immune system, (2)
the vaccine does not induce memory T cells to challenge strain unique epitopes, and (3) the immune
response to the vaccine could be biased to vaccine unique epitopes [29]. Consequently, the EpiCC score
of two sequences is improved by the presence of shared epitopes and is lowered when strain and
vaccine unique epitopes are present.
The EpiCC score is calculated using T cell epitope predictions for s and v. Each 9-mer i ∈s is
compared to a corresponding 9-mer j ∈v. The pairs of 9-mers i,j are determined from a local alignment
of s and v sequences using the Smith-Waterman algorithm from EMBOSS [30]. For i,j where one of the
9-mers has a gap in position one, that 9-mer is considered “nonexistent”, i.e. excluded from
comparison.
For each i,j and each allele a ∈A, the score of a shared T cell epitope S(i,j)a is computed only
for cross-conserved epitopes (i.e. i,j with identical residues that face the TCR and predicted to bind to
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allele a). We reasoned that epitopes with identical TCR-facing residues (TCRf), that are also predicted
to bind to the same MHC allele, are more likely to induce cross-reactive memory T cells. This is a
simple assumption because a TCR can recognize peptides with different TCRf [31], but it is a
conservative initial approach to define potential cross-reactive epitopes [32]. For class I T cell epitope
comparison, we assumed that i and j are cross-conserved, and potentially cross-reactive, if they have
identical residues in positions 4, 5, 6, 7, and 8 and are predicted to bind to a, regardless of differences
on their MHC-facing amino acids. For class II, amino acids in positions 2, 3, 5, 7, and 8 were
considered TCRf. Positions were selected based on published analysis of peptide-MHC-TCR crystal
structures [33]. S(i,j)a is calculated using predicted binding probabilities as follows:
! !, !

=! !

!

!

∙! !

!

where p is the cumulative probability in the Normal distribution for the Z-score. Since the binding of i
and j to allele a are independent, S(i,j)a, the probability of them both occurring, is the product of the
probabilities of each occurring (i.e. joint probability).
The score of a unique epitope U(i,j)a is determined for non-cross-conserved epitopes based on
binding probabilities according to these criteria:
• Score of a strain unique epitope: !" ! !

!

• Score of a vaccine unique epitope: !" ! !

> 1.64 → ! !, !
!

!

> 1.64 → ! !, !

=! !
!

!

=! !

!

Note that for any given i,j, predicted epitopes cannot be both shared and unique for allele a, but they
can be both strain unique and vaccine unique if i and j are predicted to bind allele a, and their TCRf are
distinct. For i,j where both 9-mers are not predicted to bind allele a, S(i,j)a and U(i,j)a are
undetermined.
Since the alleles in A are distinct, they are treated independently; hence, the score of shared
epitopes for i,j over the full set of alleles can be calculated as a joint probability (i.e. product of the
shared binding probabilities for individual alleles). However, given that the score of a shared epitope is
calculated only for i,j where both 9-mers are predicted to be binders, the joint probability over multiple
alleles underweights shared promiscuous epitopes. For this reason, we computed the sum of the
probabilities instead.
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For the calculation of the EpiCC score, we assume that binding of each 9-mer epitope is
mutually exclusive and uniform. Thus, E is the sum of shared and unique epitope scores of each i,j
normalized by the total number of compared pairs p to account for variable epitope densities, and by the
number of MHC alleles in A allowing for comparison of values of E determined using different
numbers of MHC alleles. Formally, the EpiCC score for sequences from a vaccine and strain is
computed as:
!(!, !)! =

1
|!| ∙ |!|

!(!, !)! − ! !, !

!

!∈!;!∈! !∈!

The sum of class I and II E(s,v)A is the total epitope-based relatedness score for s and v. Note that
U(i,j)a functions as a penalty; therefore, if ! !, !

!

> !(!, !)! , E(s,v)A is negative.

Comparison of the predicted epitope content of any sequence to itself is considered its baseline
EpiCC score (E(s,s)A; Fig. 1) and it represents the predicted epitope density of the sequence and the
binding probabilities of its epitopes. It follows that the maximum value of E(s,v)A can only be less than
or equal to E(v,v)A or E(s,s)A. For vaccines with low epitope content, E(v,v)A will be low, and E(s,v)A
will be also low, even if s and v epitopes are highly similar. Thus, low E(s,v)A can be due to low epitope
content of one or both sequences and/or low epitope relatedness between strains.
HA baseline EpiCC score comparison
We calculated the baseline EpiCC score of the HA sequence of each viral strain (E(s,s)A). So as to
evaluate whether the selection of MHC alleles had an effect on the baseline EpiCC scores, E(s,s)A was
calculated using the epitope content predicted with four different sets of MHC alleles A (SLA-I, SLA-II,
HLA-I, and HLA-II).
Comparison of HA T cell epitope content between field and vaccine viruses
We compared the epitope content (predicted using SLA alleles) of each HA to that of FS vaccine
viruses (E(s,v)A). Shared and unique class I, class II and total EpiCC scores were determined. We also
explored the relationships between protein identity and EpiCC scores using regressions. To represent
the presumed lower end of the identity spectrum, we analyzed HA from A/swine/North
Carolina/A01442548/2012 (H3N2) and A/swine/Missouri/A01727926/2015 (H4N6) viruses (GenBank
accession KC445235 and KU641621, respectively); their HA amino acid sequences had identities
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between 41.1% and 43.6% when compared to HA from FS viruses. A random sequence that had the
same number of amino acids as the average HA sequence in this data set and the average amino acid
frequencies of the proteins in the Swiss-Prot database, was also included in the comparison.
Relationship between EpiCC scores and vaccine efficacy
Based on reports of the experimental outcomes of previously published challenge studies and challenge
studies performed by Zoetis evaluating the efficacy of the FS H1γ vaccine virus, we analyzed whether a
certain level of T cell epitope relatedness of HA was associated with protection and could explain
protection observed without cross-reactive antibodies, assuming minimal variation of T cell epitope
content among internal proteins. FS was considered protective if it reduced the percentage of lung
lesions and viral titers in nasal swabs (i.e. nasal shedding) and/or in lung or lung lavage. We defined a
total EpiCC score threshold to predict protection as the lowest EpiCC score for the comparison between
the FS H1γ vaccine virus and challenge viruses, where studies demonstrated that the vaccine was
protective.
Statistical analysis
Wilcoxon matched-pairs signed rank test was used to compare baseline EpiCC score of HA sequences
defined using different sets of MHC alleles (e.g. E(s,s)SLA-I vs. E(s,s)SLA-II; E(s,s)SLA-I vs. E(s,s)HLA-I). The
same test was applied to evaluate differences between SLA class I and II EpiCC scores for each vaccine
virus. Correlation between class I and II baseline EpiCC scores was determined using the nonparametric
Spearman’s correlation coefficient (ρ). Correlation of class I and II EpiCC scores was evaluated using
the same test. The correlation between identity and EpiCC scores was determined by Pearson
correlation (r). P values (p) less than 0.05 were deemed significant. Analyses were performed using R
3.3.1 (Foundation for Statistical Computing, Vienna, Austria).

Results
HA baseline EpiCC scores, E(s,s)A
HA sequences from a range of swine IAV phylo-clusters (Fig. 2) were analyzed. Although vaccines for
influenza contain many antigens, the critical antigen (and the most variable) is HA. Thus, for this
analysis, we assumed HA as the main source of T cell epitope variability among viral strains. Across

81

the 23 H1 viruses, HA SLA class I baseline EpiCC scores, E(s,s)SLA-I, were significantly lower
(p<0.001) and less variable (0.049 (0.001); mean (standard deviation)) than class II, E(s,s)SLA-II, (0.068
(0.004)) (Supplemental Fig. 1, SLA alleles), and they were not significantly correlated (ρ= 0.18,
p=0.19). HA proteins from recently reported H1δ1 cluster viruses had the highest class II and total
baseline EpiCC scores.
To evaluate the effect of allele specificity and the breadth of coverage of the set of SLA alleles,
we compared the baseline EpiCC scores predicted using SLA alleles to that predicted using supertype
HLA alleles. Class I baseline EpiCC scores for HLA alleles, E(s,s)HLA-I, (0.063 (0.002)) were
significantly higher (p<0.001) than those predicted using SLA alleles, E(s,s)SLA-I (0.049 (0.001);
Supplemental Fig. 1). E(s,s)HLA-II (0.065 (0.004)) were significantly lower (p<0.05) than E(s,s)SLA-II
(0.068 (0.004)). The lower baseline scores observed for SLA class I alleles as compared to HLA class I
alleles may indicate that the set of SLA-I alleles selected for this study was not as broad in terms of
population coverage and might not capture all the T cell epitope differences between strains.
Alternatively, the strains may contain fewer epitopes that bind to SLA class I alleles, which is similar to
the significantly lower (p=0.04) HLA class I baseline EpiCC scores compared to those of HLA class II
using supertype HLA alleles. This result suggests that it is possible that for these sets of HAs and MHC
alleles, class I epitope content is lower than that of class II.
Comparison of HA T cell epitope content between field and vaccine viruses
We then compared the SLA class I and II epitope content predicted for HA of each field virus to that of
the vaccine viruses. Intuitively, HA proteins from similar strains will have similar epitope content. We
observed that HA sequences from viruses within the same H1 cluster or in a cluster of the same HA
lineage (cH1N1 or human seasonal) had higher scores for class I and II shared epitopes and lower
scores for unique epitopes than viruses in clusters from a different HA lineage (Fig. 3). It is noteworthy
that there were shared epitopes in all comparisons, even when comparing viruses from different HA
lineages.
Scores of shared, strain unique and vaccine unique SLA class II epitopes were significantly
higher than those for class I (p<0.001 for the three vaccine viruses), with the exception of scores of H1γ
FS vaccine unique epitopes (p=0.05). Likewise, using HLA supertype alleles, scores of class II shared
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epitopes were also significantly higher than those for class I (p<0.01) (Supplemental Fig. 2). Class II
scores of unique epitopes were also higher for OK08 H1δ1 FS (vaccine unique) and NC05 H1δ2 FS
(strain unique). Although the population coverage of the set of SLA class I may be limited, the scores
calculated using HLA supertype alleles supports that it is possible that the analyzed HA sequences had
lower class I than class II scores. Regardless, the comparison between strains was performed using
identical sets of SLA class I and II alleles, normalizing the comparisons.
Using radar plots, it is possible to visualize differences between the EpiCC scores of each
vaccine virus compared to each field virus. In Fig. 4, each axis corresponds to one virus HA sequence.
The HA sequences are sorted clockwise by nucleotide identity, relative to the IA00 H1γ FS virus. The
radar plots show that nucleotide identity did not exactly correlate with EpiCC scores (e.g. IA12 H1γ-2
and IA15 H1γ). The highest scores on each of the plots is E(v,v)A (i.e. vaccine compared to itself). HA
sequences of viruses with the same H1 cluster of the vaccine registered the highest EpiCC scores. Note
that for comparisons where the score for unique epitopes was greater than the score for shared epitopes,
EpiCC scores were below zero. For each vaccine virus class I and II EpiCC scores were significantly
different from each other (p<0.05).
Class I and II EpiCC scores correlated with the HA amino acid sequence identity of vaccines
and viral strains (r=0.86 – 0.89). However, the relationship between identity and EpiCC scores was
nonlinear second order polynomial (Fig. 5; R2=0.94 – 0.98). EpiCC scores for sequences that had
approximately 40% identity were no different from EpiCC scores for random amino acid sequence of
similar length. Similar results were observed for correlation with HA nucleotide sequence identity
(Supplemental Fig. 3). Unlike identity, EpiCC scores account only for differences in amino acids
involved in predicted T cell epitopes. For example, there are only 35 amino acids that differ between the
vaccine strain IA00 H1γ FS and the field strain CA09 H1pdm, but only 16 of these amino acids were
involved in putative SLA binders and had an effect in the class II EpiCC score. Furthermore, only four
of the residues were contained in 9-mers that were predicted to bind to three or more class II SLA
alleles.

83

Relationship between EpiCC scores and vaccine efficacy
We compared EpiCC scores with results of reported vaccine efficacy studies for the FS γ-cluster
vaccine strain (IA00 H1γ FS) against heterologous viruses representing α, β, γ, or H1pdm clusters
(Table 2) to evaluate whether certain level of HA T cell epitope relatedness between vaccine and
challenge strains was associated with protection. The primary measure for assessing vaccine efficacy in
these studies was reduction of lung lesions, with reduction of viral nasal shedding and/or virus titers in
lung or lavage fluid at necropsy as secondary outcomes. A vaccine was considered protective in our
analysis if there was a reduction of macroscopic pneumonia and virus titers in nasal swabs and/or in
lung specimens collected at necropsy. If the vaccine significantly reduced virus titers, but not lung
lesions, it was considered partially protective. Using these data, we found a total EpiCC score (sum of
class I and II EpiCC scores) threshold associated with protective efficacy for this set of challenge
studies.
For the six vaccine efficacy studies considered in this analysis, FS conferred protection against
challenge with five different H1 cluster viruses (Table 2). With the exception of one study, protection
was conferred despite low levels of HI cross-reactive antibodies (HI GMT to challenge virus ≤20). For
these studies, the threshold associated with protective efficacy was defined as the lowest total EpiCC
score (-0.002; MN02 H1β) comparing these five challenge strains with the vaccine strain (IA00 H1γ
FS). This threshold defines the white area in Fig. 6. For strains with EpiCC scores above the threshold,
the scores of shared epitopes represented at least 66.1% (0.078) of the vaccine’s baseline EpiCC score
(0.118; Supplementary Table 1), which may suggest that a field strain or a vaccine strain (or both) may
have many unique epitopes, but as long as there is a sufficient level of shared epitopes relative to the
baseline, a vaccine will be protective.
In addition, the IA00 H1γ vaccine induced partial protection against challenge with IL08 H1α.
This EpiCC score (-0.038) was considered a threshold associated with partial protection. This threshold
separates the light grey from the dark grey area in Fig. 6. IL08 H1α’s shared epitopes score was 57.6%
(0.068) of the vaccine’s baseline EpiCC score. EpiCC scores for the H1δ cluster viruses, and the IA30
cH1 and SD15 H1α strains were below this threshold in the dark grey area.
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Based on the association between total EpiCC scores of HA and vaccine efficacy, we speculate
that immunization with the IA00 H1γ FS vaccine strain could confer protection against challenge with
viruses with scores above -0.002 (white area in Fig. 6) and partial protection for challenge-vaccine
EpiCC scores between -0.002 and -0.038 (light gray area in Fig. 6), assuming minimal variation of
internal antigens. In contrast, the vaccine might not protect against viruses for which EpiCC scores fall
in the dark gray area of Fig. 6. Important differences between strain identity and EpiCC scores can be
identified; for example, the amino acid sequence of IA12 H1γ-2 virus HA is highly identical to IA00
H1γ FS (93.36%); however, its total EpiCC score (-0.023) is below the threshold associated with
protection, but above the threshold for partial protection. The low total EpiCC score is driven by a low
score for shared epitopes (0.071; 60.2%) and high score for unique epitopes (0.093; Supplemental Table
1). Nevertheless, shared epitopes might still contribute to a certain level of protection.

Discussion
EpiCC is a method for assessing the relationship between field and vaccine strains of pathogens using
predicted T cell epitope content as a metric for comparison. As compared to standard methods for
estimating vaccine efficacy, such as determining whether immunization induces cross-reactive
antibodies to the HA proteins, or measuring genetic differences by sequence similarity, EpiCC
characterizes the differences based on portions of the virus that the immune system processes and
presents to T cells that drive protective responses. The EpiCC calculation considers the epitope content
shared between sequences and penalizes strain and vaccine unique epitopes. As a first test of the EpiCC
scoring system, we compared the T cell epitope content of 20 HA sequences from different H1 clusters
present in the North American swine population to that of three HA sequences from H1 viruses
contained in a commercial swine IAV vaccine. To evaluate whether T cell epitope relatedness between
vaccine and non-homologous challenge strains was associated with protection, we compared EpiCC
scores with experimental outcomes of efficacy studies of FS H1γ vaccine virus where protection was
induced without cross-reactive HA antibodies. The results of the analysis, performed without
foreknowledge of efficacy outcomes, showed a threshold of T cell epitope relatedness that explained
protection.
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We do not yet know whether the threshold score would apply to new strains or different
vaccines. The thresholds described in this study were based on experimental data from only six vaccine
efficacy studies against challenge with cH1-lineage viruses. To evaluate whether the thresholds could
be applied to other vaccines, we compared the epitope content predicted using supertype class I and II
HLA alleles of the HA sequence of A/Brisbane/59/2007, the H1 virus in the pre-pandemic (2008-2009)
conventional influenza vaccine, and that of CA09 H1pdm. The total EpiCC score (-0.023) fell in the
area of partial protection, which is consistent with the reduced influenza-like illnesses and confirmed
infection among older adults in the absence of cross-reactive antibodies [34]. However, additional
efficacy studies would help to refine the thresholds for prediction of protection and partial protection.
Further studies are also required to extend these findings to other IAV strains, and to determine whether
EpiCC scores can be used to define thresholds of vaccine efficacy for other economically important
pathogens affecting the swine industry.
We note that the set of MHC alleles used for the prediction of epitopes influenced the scores of
shared and unique epitopes, and therefore the EpiCC scores, between vaccine strains and field viruses.
To illustrate this point, EpiCC scores calculated using binding predictions to SLA alleles were shown to
be different from those determined using a set of supertype HLA alleles. For this study, SLA allele
selection was based on frequencies determined using low-resolution haplotyping for a small number of
pigs [22]. The relevance of these differences using distinct sets of MHC alleles is unknown; however,
the distribution of SLA alleles for the North American swine population has yet to be defined, and
therefore the EpiCC scores might be different using a more comprehensive set of alleles. Development
of a high-throughput SLA typing system paired with a systematic study of SLA diversity would
improve the utility of the EpiCC analysis for swine populations not only for IAV, but also for other
economically important pathogens affecting the swine industry. Nevertheless, EpiCC scores may be
useful for estimating vaccine efficacy for populations of swine for which SLA types are well-defined
(e.g. for commercial pork operations where breeding practices limit SLA diversity).
We do not know which component of the score (shared class II epitopes or shared class I
epitopes, for example), is more important for predicting protection. Published information describing T
cell-dependent (CMI) responses elicited by swine IAV vaccines is scarce and some studies have
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reported that CMI responses to inactivated vaccines can be limited in pigs [35]. However, other studies
showed that inactivated vaccines can prime the CD4+CD8+ (double-positive) memory T cell subset
[9,36,37]. Porcine CD4+CD8+ T cells are MHC class II-restricted memory cells that have T helper
function [38]; and also express perforin and mediate cytolytic activity against virus-infected cells [39].
For the set of alleles used for epitope prediction in this analysis, we found higher scores for class II
epitopes shared between vaccines and field virus HAs compared to those of class I. Should further
studies determine that cross-reactive class II epitopes are more relevant for vaccine protection, a
weighted EpiCC score that favors class II epitopes could be applied. Furthermore, alternative versions
of the calculation (with or without scores of unique T cell epitopes) were tested. Future studies using
more vaccine efficacy data will consider all these versions to determine predictive advantage of one
calculation over the others.
EpiCC scores showing high levels of T cell epitope relatedness could explain how protection
against challenge can be observed in an absence of HI cross-reactivity in experimental efficacy studies
of the FS γ-cluster vaccine virus. The IA00 H1γ FS vaccine virus was genetically and antigenically
distinct from the challenge viruses used in the six experimental challenge studies for which efficacy
data were available. However, under the conditions of these experimental studies, vaccination provided
protection or partial protection against MN11 H1γ, IA92 H1α, OH10 H1γ, and CA09 H1pdm with HI
titers lower than 1:40 (the cutoff generally considered predictive of protection) [6,9–11]. Accordingly,
MN11 H1γ, IA92 H1α, and OH10 H1γ had the highest EpiCC scores among evaluated HA sequences
when compared to IA00 H1γ FS; CA09 H1pdm had the sixth highest score. Among these viruses, only
IA92 H1α and CA09 H1pdm have different internal genes [3]. IA92 H1α predates the emergence of
TRIG, and CA09 H1pdm was classified as a swine-origin IAV because internal and HA gene segments
were genetically similar to those in the triple-reassortant viruses circulating in North American swine
[40]. Some differences in strain-specific T cell epitope content of internal proteins should be expected.
Notwithstanding these potential differences, the IA00 H1γ FS vaccine was protective against challenge
with both strains [6,9]. This result may suggest that a certain level of shared T cell epitopes could be
associated with protection, despite the presence of unique epitopes. Antibodies to other surface antigens
may have also played a role in protection.
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This analysis was limited to T cell epitopes predicted from the sequences of the highly variable
external IAV protein, HA. The specific role of HA T cell epitopes in protection against influenza in pigs
is not yet known; however, human studies showed that vaccination with a monovalent subunit CA09
H1pdm vaccine elicited robust HA-specific CD4 T cell responses dominated by memory CD4 T cells
specific for peptides shared between the seasonal and pandemic strain. Researchers also demonstrated
that expansion of CD4 T cells specific for peptide epitopes within HA, but not NP, correlated with
neutralizing antibody response [41,42]. These results support the notion that a greater degree of CD4 T
cell cross-reactivity may be responsible for the better antibody response.
CMI responses directed to the conserved internal proteins of influenza viruses are highly crossreactive [43,44]. In pigs, two evolutionary lineages (H1pdm09 and TRIG) dominate the selection of
internal genes in the circulating influenza viruses, leading to a high degree of conservation in the
internal genes [3,23,24]. As a result, much of the antigenic variability between IAV strains circulating
in swine is determined by variable surface antigens (HA, NA and M2). We previously identified SLArestricted epitopes derived from HA, NA and M conserved in IAV from different HA subtypes [22].
Other groups have reported SLA class I-restricted epitopes in HA and NA [45,46]. Future studies will
compare the utility of including other surface antigens (such as NA and M2) in the EpiCC score to
determine whether thresholds revealed by HA-specific T cell epitope relatedness can be further refined.
Genetic sequence comparison of HA is also used for predicting potential cross-protective
efficacy of vaccines. The relationship between EpiCC scores and HA amino acid sequence identity was
nonlinear. At approximately 40% identity, epitope-based relatedness was similar to the EpiCC score of
a random amino acid sequence of the same length. And while changes in amino acids affecting T cell
epitopes can have a significant impact on the immunogenicity of an antigen [47,48], their effect on
whole antigen sequence similarity may be minimal. To illustrate this point, we found viruses that had
low EpiCC scores despite having high sequence identity. For example, when IA00 H1γ FS is compared
to IA12 H1γ-2 the EpiCC score is above the threshold set for partial protection, but below the threshold
for protection. Although H1γ-2 cluster viruses were infrequently detected in the U.S. swine population,
characterization of H1γ-2 viruses demonstrated divergent antigenic properties with viruses within the
same clade and viruses from contemporary swine H1 clusters as well as commercial vaccines,
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suggesting a potential risk of vaccine failure against H1γ-2 viruses [3]. On the contrary, EpiCC analysis
suggests that the H1γ cluster vaccine virus may induce at least partial protection against IA12 H1γ-2
virus.
In conclusion, we developed the EpiCC algorithm to assess the immunologic relatedness
between antigens based on their predicted T cell epitope content. Using EpiCC, we found that vaccine
protection conferred by the FS IA00 H1 γ-cluster, in the absence of HI cross-reactive antibodies, might
be explained by predicted T cell epitope content relatedness between challenge and vaccine viruses.
Based on these results, we proposed EpiCC score thresholds for prediction of full and partial protection.
EpiCC scores were dependent on a set of swine MHC alleles used for the predictions of epitopes; thus
future EpiCC scores for these sequences may differ from the scores reported here. As information about
SLA prevalence in North American swine populations becomes available, the impact of MHC allele
selection on EpiCC scores will be assessed further. Despite these limitations, this study provides
preliminary evidence that EpiCC may be of use as an additional measure for selecting the best-matched
vaccine virus for immunization against IAV in a herd, and possibly to help predict whether current
vaccines would protect against novel viruses introduced into the swine population. Additional data from
vaccine efficacy studies will be useful to validate and optimize these thresholds.
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Table 1. HA sequence information for swine H1 IAV.
Virus namea

Virus H1
cluster

Labelb

A/swine/Iowa/15/1930 (H1N1)

classical

IA30 cH1

GenBank
accession or
sourcec
EU139823

A/swine/Illinois/02450/2008 (H1N1)

α

IL08 H1α

CY099052

A/swine/South Dakota/A01823598/2015

α

SD15 H1α

KT356682

(H1N2)
A/swine/St-Hyacinthe/106/1991
(H1N1)

α

SH91 H1α

U11857

A/swine/Iowa/40766/1992 (H1N1)

α

IA92 H1α

KP788773

A/swine/Minnesota/00040/2002 (H1N1)

β

MN02 H1β

Zoetis

A/swine/Iowa/00239/2004 (H1N1)

β

IA04 H1β

KM198690

A/swine/Iowa/110600/2000 (H1N1)

γ

IA00 H1γ FS

Zoetis

A/swine/Minnesota/PAH618/2011 (H1N1)

γ

MN11 H1γ

Zoetis

A/swine/Ohio/02973/2010 (H1N1)

γ

OH10 H1γ

Zoetis

A/swine/Iowa/A01940123/2015 (H1N1)

γ

IA15 H1γ

KT699044

A/swine/Minnesota/A01940015/2015 (H1N1)

γ

MN15 H1γ

KT595733

A/swine/Iowa/A01410129/2012 (H1N1)

γ2

IA12 H1γ-2

KJ397936

A/California/04/2009 (H1N1)

H1N1pdm09

CA09 H1pdm

GQ117044

A/swine/Oklahoma/0726H/2008 (H1N2)

δ1

OK08 H1δ1 FS

Zoetis

A/swine/Ontario/55383/04 (H1N2)

δ1

ON04 H1δ1

DQ280212

A/swine/Illinois/PAH710/2011 (H1N2)

δ1

IL11 H1δ1

Zoetis

A/swine/South Dakota/A01823304/2015

δ1

SD15 H1δ1

KT277819

(H1N2)
A/swine/Oklahoma/A01566774/2014
(H1N2)

δ1

OK14 H1δ1

KP270784

A/swine/Minnesota/A01823864/2015 (H1N2)

δ1

MN15a H1δ1

KT699050

A/swine/Iowa/A01823426/2015 (H1N2)

δ1

IA15 H1δ1

KT356694

A/swine/Minnesota/A01940042/2015 (H1N2)

δ1

MN15b H1δ1

KT733589

A/swine/North Carolina/031/2005 (H1N1)

δ2

NC05 H1δ2 FS

Zoetis

A/swine/NC/00573/2005 (H1N1)

δ2

NC05 H1δ2

FJ638306

a

FS viruses are shown in bold font.
FS viruses have 'FS' at the end of their labels.
c
Sequences marked ‘Zoetis’ were provided by Zoetis and are considered proprietary.
b
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Table 2. FluSure XP® vaccination and challenge studies.
Heterologous
challenge

Measurement of protectiona

MN02 H1β

Percentage of
macroscopic
pneumonia
Reduced

IA92 H1α

Significantly

Significantly

reduced

reduced

Significantly

Significantly

Significantly

reduced

reduced

reduced

Significantly

Not available

Significantly

Virus

CA09 H1pdm
OH10 H1γ

IL08 H1α
a

Outcome

Ref.

Virus titers in
nasal swabs

Virus titers in
lungs

Reduced

Not available

80

Protection

7

Not available

≤20

Protection

9

≤10

Protection

6

≤10

Protection

10

≤20

Protection

11

≤20

Partial

12

reduced
MN11 H1γ

HI GMT to
challenge
virus

reduced

Significantly

Significantly

Significantly

reduced

reduced

reduced

Not significantly

Significantly

Significantly

different

reduced

reduced

Significance of outcomes was as measured and reported in the original references.
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protection

STRAIN A

STRAIN A

STRAIN A

VACCINE

Binding likelihood prediction

Binding likelihood prediction

Vaccine unique
epitopes
Strain unique
epitopes
Shared epitopes
Top 5% Top 1%

Baseline EpiCC score = Score of shared epitopes EpiCC score = Scores of shared epitopes - Scores of unique epitopes

VACCINE

VACCINE

Binding likelihood prediction

Fig. 1. Illustration
cell epitope content comparison (EpiCC) score calculation. Strain A and
Top 5% of
TopT1%
Vaccine were screened for binding likelihood to a set of four MHC alleles; 9-mers (rows) predicted to
bind to specific MHC alleles (columns) are shown in light (top 5%) or dark (top 1%) blue. The
comparison of the epitope content of Strain A to itself determines the baseline EpiCC score (left). For
the comparison between Strain A and Vaccine, scores of shared and unique epitopes are considered
when calculating the EpiCC score (right).

STRAIN A

STRAIN A

Binding likelihood prediction
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MN15 H1γ
IA15 H1γ
MN11 H1γ
99
OH10 H1γ
100
CA09 H1pdm
IA00 H1γ FS
98
99
IA12 H1γ-2
99
99 IA04 H1β
MN02 H1β
IA92 H1α
IL08 H1α
SH91 H1α
SD15 H1α
100
98
100

65
100
57

IA30 cH1

99

100
95

0.05
0.05

NC05 H1δ2
NC05 H1δ2 FS
ON04 H1δ1
IL11 H1δ1
56
97 OK08 H1δ1 FS
SD15 H1δ1
97
MN15a H1δ1
OK14 H1δ1
100
IA15 H1δ1
78
100 MN15b H1δ1

γ
β
α
δ2
δ1

0.05

Fig. 2. Phylogenetic tree for the HA nucleotide sequences of IAV field and vaccine viruses
representing H1 phylo-cluster in the North American swine. Bootstrap test results are shown next to
the branches.
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**

**

**

**

**

**

**

**

Strain
1:IA00 H1γ FS

4:OH10 H1γ

7:IA15 H1γ

10:SH91 H1α

13:SD15 H1α

16:NC05 H1δ2

19:IL11 H1δ1

22:IA15 H1δ1

2:IA92 H1α

5:CA09 H1pdm

8:IA04 H1β

11:MN15 H1γ

14:IA30 cH1

17:OK08 H1δ1 FS

20:OK14 H1δ1

23:SD15 H1δ1

3:MN11 H1γ

6:IA12 H1γ-2

9:MN02 H1β

12:IL08 H1α

15:NC05 H1δ2 FS

18:ON04 H1δ1

21:MN15a H1δ1

24:MN15b H1δ1

Fig. 3. Comparison of scores of shared and unique epitopes across strains. Scores of shared,
vaccine unique and strain unique SLA class I and II epitopes were determined for the comparison of
HA sequences from vaccine viruses and field (challenge) strains. Note that y-axes show different scales.
Solid connecting lines are included only for visualization purposes. P-values of comparisons were
calculated using one-tailed Wilcoxon matched-pairs signed rank test (**p<0.001). HA vaccine
sequences had higher scores for shared epitopes with strains belonging to the same H1 cluster or the
same HA lineage. In general, scores of class II shared and unique epitopes were significantly higher
than those of class I. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the
x-axis are described in detail in the legend below.
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OK08 H1δ1 FS

NC05 H1δ2 FS

MN15b H1δ1
SD15 H1δ1

IA15 H1δ10.02
MN15a H1δ1

OK14 H1δ1

ClassIA92I EpiCC
score
H1γ

IA00 H1γ FS
0.08

OK14 H1δ1

IL11 H1δ1

0.00
-0.02

ON04 H1δ1

0.00
-0.04

IA00 H1γ FS
0.08
0.06
0.04

OK14 H1δ1IA12 H1γ-2

CA09 H1pdm

-0.08

IA12 H1γ-2

IL11 H1δ1 IA15 H1γ

Class II EpiCC score

MN15a H1δ1

-0.02

OK14 H1δ1

-0.06

IA15 H1γ

IL11 H1δ1

OK08 H1δ1 FS

OK08 H1δ1 FS
NC05 H1δ2

MN02
OK08 H1δ1
FS H1β
SH91NC05
H1α H1δ2

0.02

0.00

0.00

OK14 H1δ1
IA12 H1γ-2
-0.04

-0.02
-0.04

-0.08
OK08IL11
H1δ1H1δ1
FSIA15 H1γ
NC05 H1δ2 FS

OH10 H1γ

CA09 H1pdm

CA09 H1pdm

IA12 H1γ-2

IA12 H1γ-2

IA15 H1γ

-0.06

IA15 H1γ

-0.12

IA04 H1β

ON04 H1δ1

MN02 H1β

SH91FSH1α
NC05 H1δ2 FSNC05 H1δ2
MN15 H1γ
NC05 H1δ2
IA30NC05
cH1 H1δ2 FS
IL08 H1α
MN15 H1γ IA30 cH1
SD15 H1α
IA30 cH1
IL08 H1α
SD15 H1α

OK08 H1δ1 FS

SD15 H1α

IA04 H1β
IA04 H1β

OK08
H1δ1H1β
FS
MN02

MN02 H1β

SH91 H1αNC05 H1δ2

NC05
H1δ2
MN15
H1γ
IL08 H1αNC05 H1δ2 FS

NC05 H1δ2 FS
IA30 cH1

IA30 cH1

SD15 H1α

MN02 H1β
SH91 H1α

SH91 H1α

MN15 H1γ
MN15 H1γ IL08 H1α
SD15 H1α
IL08 H1α

Fig. 4. EpiCC score comparisons between HA sequences of FS vaccine viruses and field viruses.
Each axis corresponds to the HA sequence of one virus. EpiCC score = Scores of shared epitopes Scores of strain and vaccine unique epitopes.
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OK08 H1δ1 FS

NC05 H1δ2 FS

ON04 H1δ1
IA00 H1γ FS IA04 H1β

ON04 H1δ1IA04 H1β
ON04 H1δ1

IA00 H1γ FS

IA00 H1γ FS
MN15b H1δ1 0.08
IA92 H1γ
IA92 H1γ
SD15
MN11 H1γ
MN11 H1γ
IA00H1δ1
H1γ FS
0.06
MN15b H1δ1 0.08
IA92 H1α
OH10 H1γ
OH10
H1γIA15 H1δ1
0.04
SD15
H1δ1
MN11 H1γ
IA15 H1δ1 MN15a
CA09H1δ1
H1pdm

0.00

-0.04

-0.12

NC05 H1δ2 FS

0.04

0.02

OH10 H1γ
MN15aCA09
H1δ1H1pdm

-0.04
-0.06

IL11 H1δ1

0.04

OK08
H1δ1FSFS
IA00 H1γ

NC05 H1δ2 FS

MN15b H1δ1
IA00 MN11
H1γ FSH1γ
SD15 H1δ1
0.06
MN15b H1δ1 0.08
IA92 H1α
OH10 IA15
H1γMN11
H1δ1H1γ
SD150.04
H1δ1

IA15 H1δ1
MN15a H1δ1

IA00
H1γFS
FS
OK08
H1δ1

IA00 H1γ FS

R2 = 0.95

R2 = 0.97

R2 = 0.98

R2 = 0.94

R2 = 0.94

R2 = 0.97

Fig. 5. Relationship between EpiCC scores and identity. The second order polynomial relationship
between class I (top), II (bottom) EpiCC scores, and amino acid identity for each FS virus are shown.
R2 of regression models are shown. H3N2, H4N6 and a random sequence were included in this analysis
to represent the lower end of the identity range. Interestingly, there were instances where viruses had
low EpiCC scores despite high identity (e.g. class II epitope content of IA00 H1γ FS compared to SD15
H1α).

100

Protec)on

Par)al protec)on

No protec)on

IA00 H1γ FS

Total EpiCC score
MN15b H1δ1
SD15 H1δ1
IA15 H1δ1
MN15a H1δ1

IA00 H1γ FS
0.12

0.04

IA92 H1α (P)
MN11 H1γ (P)
OH10 H1γ (P)
CA09 H1pdm (P)

-0.04

OK14 H1δ1

-0.12

IA12 H1γ-2

IL11 H1δ1

-0.20

IA15 H1γ

ON04 H1δ1

IA04 H1β

OK08 H1δ1 FS

MN02 H1β (P)*

NC05 H1δ2
NC05 H1δ2 FS
IA30 cH1

SH91 H1α

SD15 H1α

MN15 H1γ
IL08 H1α (PP)*

Fig. 6. Definition of threshold for prediction of vaccine efficacy prediction. Total EpiCC scores
(blue line) for the comparison of H1γ FS and each viral strain are shown. The FS γ-cluster vaccine
strain was protective or partially protective against challenge with viruses annotated as (P) or (PP),
respectively. The rest of the viruses were not tested as challenge strains. Protection and partial
protection thresholds (black lines) defined three areas shown in white (protection; total EpiCC score
above -0.002), light gray (partial protection) and dark gray (no protection). Viruses used to set the
thresholds are marked with an asterisk (*). We hypothesize that FS would confer at least partial
protection against challenge with viruses that had EpiCC scores outside the darker gray region.
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CHAPTER 5
Conclusions
The development of immunoinformatics tools has had a significant impact on human
immunology research, discovery of immunogenic epitopes and design of vaccines for diverse
pathogens. One of the main applications of immunoinformatics is T cell epitope prediction due to their
critical role in cell-mediated immunity (CMI). T cell epitope mapping algorithms can easily analyze
complete proteomes of any size to identify candidates for further experimental validation. However,
immunoinformatics tools are very limited for non-human species. In this thesis, concepts and
information used to construct immunoinformatics methods for humans were applied to develop novel T
cell epitope-based immunoinformatics tools for swine.
PigMatrix has been designed to map swine T cell epitopes using the pocket profile method.
This method was applied to overcome the lack of SLA-specific binding data required to train and test
predictors by leveraging predefined binding preferences for HLA. The pocket profile method has been
previously applied for prediction of binding to HLA alleles with limited binding data [1,2]. This is the
first formal application and evaluation of the method for a non-human species. Different approaches
were tested to define pocket residues (based on SLA or HLA structures) and similarity between SLA
and HLA pockets for selection of the best human match. Without any training step, PigMatrix achieved
a favorable predictive performance, comparable to or better than other available methods for SLA class
I alleles. It is noteworthy that PigMatrix is the first tool designed for prediction of SLA class II T cell
epitopes.
The current implementation of PigMatrix compares the sequences of an SLA pocket to a
library of HLA pockets and calculates a similarity score to identify the best human match and infer
binding preferences. The library of HLA pockets is comprised of HLA supertype alleles, but it can be
readily extended to include more alleles with defined binding specificities. Thus, it would be possible to
find better human matches, which may improve PigMatrix predictions. Furthermore, weighting the
similarity score by conservation of key contact residues or biochemical properties in the pocket may
also improve the selection of the best human match.
Larger datasets of SLA-restricted peptides are required to further evaluate the PigMatrix

102

approach and improve the predictions. To generate quantitative binding data and test PigMatrix, binding
assays for commonly expressed SLA molecules could be developed. These assays would provide
valuable information to better define binding preferences and potentially develop predictions based on
SLA specificities rather than HLA pocket preferences. Currently, binding assays are limited to only
three SLA class I alleles [3]. In addition, crystallographic structures of diverse SLA molecules would
further expand our understanding of the SLA binding pockets and their specificities; only two crystal
structures of SLA class I alleles are currently available [4,5]. Similar to class I predictions, class II
predictions may improve if pocket residues are defined based on SLA crystal structures rather than
structures of HLA molecules.
Based on the initial encouraging results of PigMatrix, predictions were extended to SLA alleles
reported to be prevalent in commercial pigs and applied to identify potentially immunogenic IAV
peptides. IAV is considered one of the most important infectious disease agents affecting North
American swine [6,7]. The majority of currently licensed swine IAV vaccines consist of whole
inactivated viruses administered with adjuvant by intramuscular injection [8]. This platform primarily
induces systemic IgG antibody responses to the surface glycoproteins, mainly HA [8,9]. However,
antibody-mediated immunity does not typically provide protection against divergent strains of IAV
[9,10]. Conversely, CMI can be broadly cross-reactive to a variety of IAV subtypes [11–15]. Moreover,
CMI contributes to clearance of virus and reduced symptom severity and virus shedding [16,17]. A
vaccine that induces CMI and reduces morbidity could prevent anorexia and weight loss, which cause
significant economic impact to pork producers. Therefore, identification T cell epitopes conserved in
diverse IAV represents the first step toward the development of a potentially broadly protective vaccine.
So, PigMatrix was used to screen complete proteomes of representative IAV strains in U.S. swine for
class I and II T cell epitopes. A prototype epitope-based DNA vaccine encoding strings of class I and II
epitopes was developed to evaluate immunogenic responses to the putative epitopes. Eleven T cell
epitopes induced specific IFNγ recall responses in pigs vaccinated with the prototype vaccine. Recall
responses to peptides were not observed in pigs immunized with the inactivated commercial vaccine,
despite containing similar internal antigens. This result shows that the epitope-based vaccine promoted
more efficient processing and presentation of its own epitopes as compared to whole-protein-based
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vaccines.
In this immunogenicity study, SLA-typing performed at the end of the study revealed that the
SLA alleles used for the prediction were not prevalent in the study cohort, which highlights that the lack
of information on SLA frequencies in the U.S. population represents a challenge for the development of
T cell epitope predictors for swine. Cohort-specific predictions developed to re-evaluate the putative
epitopes showed lower binding likelihood for 46 out of 48 epitopes and were particularly effective
identifying non-immunogenic peptides. PigMatrix might be applied to identify T cell epitopes from
other swine pathogens, which could significantly speed the development of novel vaccines for
infectious diseases in pigs.
Further studies would apply PigMatrix using a more comprehensive set of SLA alleles to
identify and add peptides to the set of highly conserved and immunogenic IAV sequences to be
included in an epitope-driven vaccine. In addition to SLA binding assays and standard recall assays
using blood from naturally infected or vaccinated pigs, the selection process of peptides can be
optimized by implementing T cell assays currently applied to evaluate peptide immunogenicity for
human studies using naive PBMCs [18]. In this protocol, before performing ELISpot assays, PBMCs
are cultured with individual peptides over 8 days to expand peptide-specific T cells ex vivo. Results of
this method, in a preliminary evaluation using naïve blood from pigs, showed that it is possible to
measure specific IFNγ recall responses upon restimulation with peptides (unpublished).
The prototype vaccine tested, developed as a tool to measure peptide immunogenicity, was
designed to target the putative class I and class II epitopes to the endogenous and exogenous antigen
presentation pathways, respectively. In this study, pigs were vaccinated three times intramuscularly, but
future vaccine efficacy studies could test other immunization methods like gene gun or electroporation.
These methods could enhance the in vivo transfection (i.e. introduction of nucleic acids into eukaryotic
cells) efficiency of the DNA vaccine [19]. To date, three DNA vaccines have been licensed for
veterinary use (West Nile Virus vaccine for horses [20], infectious hematopoietic necrosis virus vaccine
for salmon [21], and a canine melanoma vaccine [22]). Moreover, the first licensed electroporationdelivered product and first licensed gene therapy was the growth hormone-releasing hormone for use in
swine [23]. The development of these products illustrates the advancements in DNA plasmid
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technology and its application for animals both big and small. Other methods could be also evaluated to
deliver immunogenic T cell epitopes. For example, alphavirus-like replicon particle (RP) technology
has recently been approved by the USDA as a vaccine for swine IAV. This vaccine uses RP to deliver a
sequence that encodes an H3 HA [8]. RP can be engineered to deliver peptides and an HA component
to potentially induce both CMI and humoral responses.
Information about SLA allele diversity in the U.S. swine population is critically important to
develop a more comprehensive set of predictions that target the most prevalent SLA alleles. A
commercially available high-throughput method for high-resolution SLA-typing would improve the
ability of researchers and producers to determine SLA diversity. Researchers in other countries have
recognized the importance of SLA diversity for vaccine development and studies to identify commonly
expressed haplotypes have been conducted [24]. Once the prevalence and diversity of U.S. swine SLA
are better understood, it may be possible to cluster SLA molecules into supertypes. The concept of
supertypes has been applied to HLA for selection of few representative alleles from different clusters to
cover a high percentage of the HLA diversity in human population [25,26]. An epitope-based vaccine
based on peptides predicted to bind SLA supertype alleles could induce immune responses in pigs
expressing diverse alleles.
A novel tool for epitope content comparison called EpiCC was developed leveraging
PigMatrix predictions. This method estimates the relationship between variable viruses based on their
putative T cell epitope content to predict cross-protection. For influenza and other viruses, sequence
data and antibody cross-reactivity are commonly used to predict vaccine-induced protection. However,
previous efficacy studies demonstrated that in the absence of cross-reactive antibodies, a commercial
swine IAV vaccine was capable of inducing protection or partial protection against heterologous
challenge strains [9,27–31]. The EpiCC analysis showed that T cell epitope-based relatedness between
HA proteins of the vaccine and challenge strains was associated with vaccine-induced protection. The
results also demonstrated that the T cell epitope content depends on the set of MHC alleles used for the
predictions of epitopes. EpiCC analysis may complement current methods for vaccine selection in
outbreak situations and strain selection for vaccine production.
Future studies of EpiCC could explore different criteria to define shared and unique epitopes.
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The current definition of shared (or cross-reactive) and unique epitopes is very stringent (only epitopes
predicted to bind to the same SLA allele with identical TCR-facing residues were considered crossreactive); it is likely that this approach underestimates the full set of shared epitopes between vaccines
and viruses, but it provides a reasonably conservative means to determine the minimum shared T cell
epitope content. In reality, epitope cross-reactivity is conformational, hence, it is possible that epitopes
with different TCR-facing residues and completely different sequences can be recognized by the same
TCR [32,33]. EpiCC will be tested applying less restrictive criteria for cross-reactivity allowing for
conservative mismatches between TCR-facing residues or applying a threshold of similarity [34]. In
addition, the initial model assumed equal importance for vaccine and strain unique epitopes as well as
for class I and II T cell epitopes; further EpiCC analyses will evaluate the impact of incorporating
weighted scores.
The EpiCC analysis was restricted to HA sequences from 23 viruses representing diverse
clusters of field strains; we assumed limited T cell epitope variation of other antigens. However, the
same approach can be applied to multiple antigens or to complete proteomes of influenza strains or
other pathogens. Future studies of large-scale surveillance data will be performed to identify circulating
or novel viruses distantly related to current vaccines for further experimental evaluation to determine
potential risk of vaccine failure. It would also be possible to identify viruses with low T cell epitope
relatedness with vaccine viruses despite high sequence similarity (or vice versa); challenge studies with
these viruses will provide evidence of the role of T cell epitopes in protection. Predicted T cell epitopes
will be synthesized and tested individually using PBMCs from vaccinated pigs pre- and post-challenge
to evaluate PigMatrix predictions as well as responses to shared and unique epitopes. In addition, more
sophisticated methods will be explored to visualize the T cell epitope content and the epitope-based
relationship among large number of viruses. For example, in preliminary studies, we have tested
multidimensional scaling and distance trees to represent T cell epitope-based distances (unpublished).
Moreover, EpiCC analysis has obvious applications to human vaccine studies, where epitope content
could be compared for predictions using HLA alleles.
The preliminary success of PigMatrix and EpiCC opens the door for the development of other
immunoinformatics tools to study the immunogenicity of swine pathogens and to identify potential
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regulatory T cell epitopes. Previous large computational studies comparing predicted human T cell
epitopes have demonstrated differentiable patterns of TCR cross-reactivity with self, associated with
different T cell phenotypes [35,36]. JanusMatrix is the tool developed to perform this analysis; it uses
EpiMatrix for prediction of human T cell epitopes and then compares their TCR-facing residues against
T cell epitopes predicted within the human proteome, human pathogens, and human microbiome to
identify epitopes with identical TCR-facing residues [35]. JanusMatrix has shown that regulatory T cell
epitopes have greater TCR cross-reactivity with human proteins than effector T cell epitopes [35].
Integrating both MHC binding and TCR cross-reactivity to self, the Janus Immunogenicity Score has
been developed to predict viral and bacterial immunogenicity potential [36,37]. These analyses have
provided evidence of a pathogen mechanism of ‘immune camouflage’ to avoid immune recognition by
reducing the MHC and/or TCR binding of their peptides. We are now in the unique position to extend
these approaches to swine. Prediction of potential regulatory T cell epitopes may have a significant
impact in swine vaccine design. For example, porcine reproductive and respiratory syndrome virus
(PRRSV) causes one of the most devastating swine diseases worldwide. One of the mechanisms
associated with the ability of PRRSV to negatively modulate the host immune system is the induction
of regulatory T cells [38]. A version of JanusMatrix equipped to predict swine T cell epitopes could
help to find potential regulatory T cell PRRSV epitopes for experimental evaluation. Thus, PigMatrix
and JanusMatrix could help to better classify pathogen epitopes, which will improve future vaccine
designs.
Animal researchers are starting to recognize the value and diverse applications of
immunoinformatics in the veterinary field. The development of predictive tools for swine T cell
epitopes, their application to the analysis of existing vaccines, and the design of new vaccine
prototypes, demonstrates the potential of immunoinformatics to aid and accelerate swine vaccine
development and paves the way for future advancements for other important livestock species.
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APPENDICES
Supplemental information for Chapter 2
Supplemental Table 1. Peptide database.
Exp: Experimental results; 0: Non-binders, 1: Binder
SLA-1*0401
Sequence
ALTDLGLIY
AMYDPQTYY
ASAAHLAAY
ASFAAQLFY
ASYAAAAAY
ASYAGAGAY
ASYGAGAGY
ASYQFQLPY
ATAAATEAY
ATAWRTGGY
ATDFKFAMY
ATEDPSSGY
ATIMPHNLY
ATTFARFLY
ATVKGMQSY
ATYQRTRAL
AVDVDDGHF
AVEDFLAFF
AVEGGLYPV
AVSFRNLAY
CSDETTLYY
CTDDNALAY
CTELKLSDY
CTLNKSHLY
DSDDWLNKY
DTEDNVPPW
EIAQHGAWY
EISGSSARY
ESDMEVFDY
ESENISEPY
ESSDDELPY
ETESVNSNY
EVAGAGSGF
EVDQTKIQY
FLYPSWSLY
FSIPVTFSY
FTAMQALDY
FTDNNELEF
FTFWTFANY
FTIRDVLAY
FTYAPAGMY
GSDGGLDDY
GSQYVSLAY
GTDSGFAAY
GTDSNGMLW
GTEKLTITY
GTEYRLTLY
GTFDLGGLY
GTTEVNGLY
GVEPGHAFY
HIASMRRNY

Exp
1
1
1
0
1
1
1
1
1
1
1
1
0
1
1
0
1
1
1
1
1
1
1
0
0
1
1
1
1
0
0
1
1
1
1
0
1
1
1
1
1
1
0
1
1
1
0
0
0
1
1

SLA-2*0401
Sequence
AAKHMSNTY
ASYQFQLPY
ATAAATEAY
ATAVNQECW
DTRAIDQFF
ESLLHQASW
ESPSSDEDY
FAHDDRYLY
FGMPNPEGY
FQMDYSLEY
FSSQLGLFY
FSVPLDEGF
FTFWTFANY
FTIRDVLAY
HMMAVTLFY
HQYPANLFY
HSNLNDATY
HTAEIQQFF
HTSALSLGY
IIYYQLAGY
ISRQIHWCW
ISVQPLWEW
ITLKVFAGY
KSAAIDGEY
KSLDNYQEW
KSWPAAIDW
MANIFRGSY
MLYPRVWPY
MNYAAAAAY
MTAASYARY
MTAHITVPY
MTRGLLGSY
MTRVTNNVY
MVASQLARY
MVFQNYALY
MYADDTAGW
QQYHRFGLY
QTWHGDAPY
QTYMYTGQY
RSVWIPGRW
RVYNNTARY
RVYPNPEVY
RYQAQQVEW
SAYYLDIGF
SLRPNDIVY
SSLPSYAAY
SSMNSDAAY
SSNAKNSEW
SSNPVMSRF
SSVGVTHGY
SSVSSFERF

Exp
0
1
1
0
0
1
0
0
0
0
0
0
1
1
0
0
0
0
1
1
0
0
1
0
0
0
0
0
1
1
1
1
0
1
1
0
1
0
0
1
0
0
0
0
0
1
0
0
0
1
0

SLA-3*0401
Sequence
AMYDPQTYY
ASYAAAAAY
FLYPSWSLY
FQMDYSLEY
GMFANRWII
GMFSWNLAY
HMMAVTLFY
HQYPANLFY
ITMVNSLTY
KARARLLSM
KMFHGGLRY
KNNFWFWEY
KRIRLKHIF
KRMMMNLNY
KSFFSRLNW
KSYEHQTPF
KTLKGGWFF
LNIMNKLNI
LNWFEIWIV
LSNFMLWQF
MARWITWAM
MMHASTSPF
MQYLNPPPY
RARKRGITM
RAYRNALSM
RIRAANLPI
RIYSHIAPY
RLASYGLYY
RLFFIDWEY
RLRRRRHPL
RLYPFGSYY
RMFKRVFNM
RMFLAMITY
RNMSRIFPY
RNNDPTLPY
RQHPGLFPF
RRARYWLTY
RRFFPYYVY
RRFKYLLNV
RRFNRTKPM
RRLHRLLLM
RRMATTFTF
RRRQWASCM
RRSRRSLTV
RRVRRRVLV
RSFRIHILF
RTFDRFFEE
RTLDTLALY
RVFKETLFL
RVFNNYMPY
RVFYFAIFY
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Exp
0
0
0
0
0
0
0
0
0
1
0
1
1
1
1
1
1
1
0
0
1
0
0
1
1
1
0
0
0
0
0
1
0
1
0
0
1
1
1
0
1
1
1
1
0
0
0
0
0
1
0

SLA-DRB1*0201
Sequence
AAAPSTTTALDTTPN
AAFVTNSTVADELGR
ADALAPVVVEGERAT
ADPEYFDEPPRPELP
AEWILKTLVNTEHAY
AFLICLIKVLRGQIV
AHGRKRIVCRERLFS
AHGVFNPEFGPAALS
ALKLMEKREYKFTCQ
ALLALYAAAIAAAPS
ANHCSDAMNIMFEEV
APASPEAGAVSTPPV
APGLPWALQGKRRGA
AQMHSNNGPQIGSAV
AQYRNVWDVDYSAFD
ARAMLALLALYAAAI
ASLAHADALAPVVVE
ATLSKNKNCILCTVC
AVHSGPDEYRRLFEP
AVSFGCAVFPRAGET
CAVFPRAGETFEVRF
CDGLCVPPEARLAWS
CRYDKDADINVVTQA
DAADALAPSLRCEAV
DAETEGVYTWRVLSA
DAMNIMFEEVFNTDF
DGLDAMEPDTAPGLP
DHAADTVYHLGACAE
DKGFVLGHSITDVTF
DTTPNGGGGGNSSEG
DYRYAISSTNEIGLL
DYTCRLEGLPSQLPV
DYYPRRSVRLRWFAD
EAGAVSTPPVPPPSV
EALKPHFKSLGQTIT
EAMTNYAKEGIQFMK
EGFAVCDGLCVPPEA
EHPVDAAFVTNSTVA
EIRPMEKVRAGKTRI
EKREYKFTCQTFLKD
EKVRAGKTRIVDVLP
ELSPSPPPTPAPASP
ENALLVALFGYVGYQ
ENKRITVEGGMPSGC
EPFRAVCVVRDYYPR
EPIQLAYNSYETQVP
ERLFSARVGDAVSFG
ERVHVMRKTKLAPTV
FDEPPRPELPRERLL
FEDTQRYDASPASVS
FEVRFYRRGRFRSPD

Exp
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
1
1
0
0
0
0
0
1
0
0
1
0
0
0
0
0

HMMAVTLFY
HSDDALFIY
HTAAPWGSY
HTSALSLGY
IAGFIEGGW
ISAYTHWYY
ITAGYNRYY
ITDITKYLY
ITDITSPLW
ITDYIVGYY
ITFQSILGY
ITTFFTFAY
IVDCLTEMY
IVDINVKDY
KIAPLMVAY
KLDAWLLPF
KLDPTNTLW
KMARLGKGY
KMFHGGLRY
KSDGTGTIY
KSDLQPPNY
KSNRIPFLY
KSTDSESDW
KTAVVVTRY
KTFEWGVFY
KVFFGPIYY
LIDGRTSFY
LLDGLLAWY
LSDDAVVCY
LSTASSWSY
LTAHYCFLY
LTDDMIAAY
LTDSDSPTY
LTFLDCLYY
LTMDREMLY
MADSFKSDY
MIDSDEWVY
MIEPRTLQY
MIGGIGRFY
MLASIDLKY
MSAIVSCRY
MSNEGSYFF
MSSAAHLLY
MSWESTAEY
MTAASYARY
MTAHITVPY
MTRGILGSY
MTRGLLGSY
MTRVLPFTY
MTRVTNNVY
MTSGSSSGF
NADTLCIGY
NIDNMCHLY
NSDTVGWSW
NTDAFSREY
QIGNIISIW
QSAANMYIY
QTDNDIWFW
QTDNQLAVF
QTDPLWQKY
QTEENLLDF
QTNLYNLLY

0
1
0
1
0
1
0
1
1
1
0
0
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
0
1
1
0
0
1
1
1
1
0
1
0
1
1
1
1
0
0
0
0
1
1
1
1
1
1
0
1
1
1
1
1

STEPPMLNY
STFATVLEY
TVYNGTSKY
VSIPVTNTW
VSRLEHQMW
VSYAAAAAY
VTEPGTAQY
YANMWSLMY
YAQMWSLMY
YAYNSSLLY
YLSGIAQYY
YSRMLYIEF
YSYIFLSSY
YTASVVAAY
YTGPDHQEW
YTIGIGAFY
YTITYHDDW
YTNPQFNVY
YTSDYFISY

0
0
0
1
0
1
0
0
0
0
1
0
0
1
0
1
0
0
1

RVRRLNWAA
RVYPNPEVY
RWFVRNPFF
RYFTVAFLF
SARRRHLVF
SMFDSWGPF
SQYHRFPIY
SRWSRKMLM
SSMNSFLLY
TSFASSWIY
TTRHRKPTY
TVFYNIPPM
VMFRNASEY
VSYAAAAAY
VTFWGFWLF
YAYNSSLLY
YMIGYTAYY
YRFRFRSVY
YSRPWNWTF
YSYIFLSSY
YTFFFTQYF
YTYATRGIY
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1
0
0
0
1
0
0
0
0
1
0
0
0
0
0
0
0
1
1
0
0
0

FGTHFAQYRNVWDVD
FNTDFGFHPNAEWIL
FQGLFEIPSYRSLYL
FRSPDADPEYFDEPP
FSEALRPHVYHPAAV
FSSANASLAHADALA
GACAEHPGLLNVRSA
GCNPDVDWQRFGTHF
GDKATAHGRKRIVCR
GERATVANVSGEVSV
GEVSVRVAAADAETE
GFHPNAEWILKTLVN
GGGGGNSSEGELSPS
GKTRIVDVLPVEHIL
GLAAADAADALAPSL
GLIVDTRDVEERVHV
GLSAPPVLFGEPFRA
GLSTAENALLVALFG
GQTITPADKSDKGFV
GVYTWRVLSANGTEV
HFKSLGQTITPADKS
HMDYGTGFYKPVMAS
HPAAVSVRFVEGFAV
HPGLLNVRSARPLSD
HSVLGTANAPLSTYE
ICAAGSFKVTALNVV
IFSKHKGNTKMSEED
IGRFCAQMHSNNGPQ
IGSAVGCNPDVDWQR
ILAIVLVIMATCVYY
ILSFARRGTIQEKLI
INTILNNIYVLYALR
KAILISCISNKWQFI
KALFRRCAADYASRL
KFTCQTFLKDEIRPM
KGNTKMSEEDKALFR
KHKVRNEVMVHWFDD
KKFFLLSSRVKELII
KKGKNFSFAGTIIEG
KLASSAFSGLFG
KTLEAILSFARRGTI
KTLVNTEHAYENKRI
LAPSLRCEAVWYRDS
LAPTVAHGVFNPEFG
LDGPVDYTCRLEGLP
LEGLPSQLPVFEDTQ
LGHSITDVTFLKRHF
LIKVLRGQIVQGVIW
LNEGVVLDEVIFSKH
LVIMATCVYYRQAGP
LYALRRHYEGVELDS
MEPDTAPGLPWALQG
MFEEVFNTDFGFHPN
MMASLARAMLALLAL
MPSGCSATSIINTIL
MRKTKLAPTVAHGVF
MSEEDKALFRRCAAD
NDWFSKLASSAF
NGTEVRSANVSLLLY
NGTVGPEVEAALKLM
NKDPRLNEGVVLDEV
NNGPQIGSAVGCNPD

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
1
1
1
1
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
1
0
0
0
0

QTWHGDAPY
QVSRPMFLY
RADSMMLGY
RIARFHRPY
RLASYGLYY
RMFLAMITY
RSADGSPPY
RTDAWSYPV
RTLASGLIY
RTWAYHGSY
RTWFHGSLY
RTWHYCGSY
RTWNYHGSY
RVERIKSEY
RVFPGDHFY
RVSTGLYRY
SSDDIPPRW
SSDISFIKY
SSDLRSWTF
SSFERFEIF
SSMNSFLLY
SSSFSFGGF
SSVGVTHGY
STAPTGSWF
STFATVLEY
STYQPLPLY
SVAMCRTPF
SVDGFRASY
SVEMNAPNY
SVEVKLPDY
TIDKSSPLY
TLELRSRYW
TMDVNHPIY
TQDLFLPFY
TSDGFINGW
TSSARSSEW
TTSDFFVNY
TVYNGTSKY
VAGGTGSVY
VLDKWNTNY
VSALRLFNY
VSDGGPNLY
VSDGPPTGY
VSFNQNLEY
VSYAAAAAY
VTDPGGLYY
VTIGNAYIY
VTRGAVLMY
VVAANRSAF
VVDALRNIY
WSQDPTMLY
WTGMVDGWY
WVAGVQLLY
YAQMWTLMY
YIFFASFYY
YLSGIAQYY
YSAEALLPY
YSYIFLSSY
YTASVVAAY
YTDKIAMSY
YTFEPHYFY
YTSDYFISY

1
1
1
1
1
0
1
1
1
1
1
0
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0
1
1
1
0
1
1
0
0
1
0
0
1
1
0
0
0
1
0
1
1
0
1
1
0
1

NNIYVLYALRRHYEG
NPEFGPAALSNKDPR
NSSEGELSPSPPPTP
NSTVADELGRRTRVS
NVRSARPLSDLDGPV
PAALSNKDPRLNEGV
PADKSDKGFVLGHSI
PASVSWPVVSSMIVV
PDEYRRLFEPFQGLF
PEVEAALKLMEKREY
PPPSVSRRKPPRNNN
PPPTPAPASPEAGAV
PRNNNRTRVHGDKAT
PVLFGEPFRAVCVVR
PVMASKTLEAILSFA
PVVVEGERATVANVS
QEKLISVAGLAVHSG
RADVPGLAAADAADA
RAGETFEVRFYRRGR
RCAADYASRLHSVLG
RCEAVWYRDSVASQR
RERLLFSSANASLAH
RHYEGVELDSYTMIS
RIVCRERLFSARVGD
RLAWSDHAADTVYHL
RLFEPFQGLFEIPSY
RPELPRERLLFSSAN
RPHVYHPAAVSVRFV
RPLSDLDGPVDYTCR
RQLSSNYILELLYKF
RRGTIQEKLISVAGL
RSANVSLLLYSQPEF
RSVRLRWFADEHPVD
RTRVHGDKATAHGRK
RTRVSVVNVTRADVP
RVAAADAETEGVYTW
RVLSANGTEVRSANV
RWFADEHPVDAAFVT
RYDASPASVSWPVVS
SATSIINTILNNIYV
SEGKIRQLSSNYILE
SLLLYSQPEFGLSAP
SMIVVIAGIGILAIV
SQLPVFEDTQRYDAS
SQPEFGLSAPPVLFG
SQSPYVVVATNAIES
SRRKPPRNNNRTRVH
STPPVPPPSVSRRKP
SVAGLAVHSGPDEYR
SVRFVEGFAVCDGLC
SYFQQYMLKGEYQYW
TANAPLSTYEAIKGV
TASALYLISYYVIPQ
TDVTFLKRHFHMDYG
TEHAYENKRITVEGG
TFLKDEIRPMEKVRA
TGFYKPVMASKTLEA
TLILILPTYELTKLY
TRDVEERVHVMRKTK
TRVWNSASTTAFLIC
TTLLNGSAFYLVCPI
TTTALDTTPNGGGGG
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0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
0
1
1
0
1
0
0
0
0
1
0
1
1
0

YTYPCIPEY
YVFVGSSRY
YVFVGTSRY
YVYFYDLSY

1
0
1
1

TVEGGMPSGCSATSI
TVYHLGACAEHPGLL
VALFGYVGYQALSKR
VANVSGEVSVRVAAA
VASQRFSEALRPHVY
VCVVRDYYPRRSVRL
VDVLPVEHILYTRMM
VDWQRFGTHFAQYRN
VEHILYTRMMIGRFC
VELDSYTMISYGDDI
VELYYKGTTIKLDFN
VLDEVIFSKHKGNTK
VPPEARLAWSDHAAD
VVASDYDLDFEALKP
VVCQSNNKMTDESEY
VVNVTRADVPGLAAA
VWDVDYSAFDANHCS
WALQGKRRGALIDFE
WPVVSSMIVVIAGIG
WYRDSVASQRFSEAL
YAAAIAAAPSTTTAL
YASRLHSVLGTANAP
YDLDFEALKPHFKSL
YEPRDSYFQQYMLKG
YGDDIVVASDYDLDF
YRRGRFRSPDADPEY
YSAFDANHCSDAMNI
YTMISYGDDIVVASD
YTRMMIGRFCAQMHS

114

0
0
1
0
0
0
0
0
0
0
1
0
0
0
1
0
0
0
0
0
0
0
1
1
0
0
0
0
0

Supplemental Table 2. HLA crystal structures.
Allele

PDB

HLA-A*0101

4NQV

HLA-A*0201

3MRE

HLA-A*0201

3MRG

HLA-A*0301

3RL1

HLA-A*1101

1X7Q

HLA-A*2402

1P7Q

HLA-A*6801

4HWZ

HLA-B*0702

4U1H

HLA-B*0801

4QRS

HLA-B*2705

2A83

HLA-B*3501

2CIK

HLA-B*4403

1N2R

HLA-B*5101

1E27

HLA-DRB1*0101

1T5W

HLA-DRB1*0301

1A6A

HLA-DRB1*0401

1J8H

HLA-DRB1*1501

1YYM
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Supplemental Table 3. Contact residues in the SLA class II binding pockets based on HLA
contacts (Hc).

SLA

Pocket (peptide position)

position A(1) B(4) C(6) D(7) E(9)
9H
11L
13F
26L
28E
30Q
37F
38L
47Y
57D
60D
61W
67L
70Q
71R
74E
78Y
81H
85I
86L
89F
90L
Positions of the residues in the SLA binding pockets are shown. The first column (SLA position) is the
residue and position in the SLA-DRB1*0201 protein sequence (Genbank:61652983). The next columns
show, shaded in gray, the positions involved in pockets A through E that interact with specific positions
of the peptides (peptide position).
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2004(H3N2)

A/turkey/Ohio/313053/

1998(H3N2)

A/swine/Texas/4199-2/
361630452

340784749

421920014

02011/2008(H1N2)
A/swine/Minnesota/

A01301731/2012(H1N2)

304272397

A/swine/Minnesota/

2007(H1N1)

A/swine/Ohio/511445/

2010(H1N1)
197344175

227809823

A/California/04/

2009(H1N1)
A/swine/Illinois/5265/

PB2

Strain

GenBank id

367462658

340784753

421920016

304272373

197344177

332384205

PB1, PB1-F2

367462657

340784756

421920018

304272351

197344180

227977113

PA

371574609

340784760

421920020

304272327

197344171

290873719

229535948

HA

367462656

340784762

421920022

304272303

197344182

332384201

NP

370321100

340784766

421920024

304272279

197344173

290873721

332384199

NA

361630450

340784768

421920026

304272249

197344184

290873723

332384196

M2, M1

361630451

340784771

421920029

304272213

197344187

332384209

NS2, NS1

Supplemental Table 1. GenBank identification numbers of gene sequences of proteins expressed by representative swine IAV.

Supplemental information for Chapter 3

Supplemental Text 1. Concatemer construct sequences.
>Class I concatemer construct
cggatctaccagattctggccatctacatcaccatcggcaagtgccccaagtactctctgctgaccgaagtggaaacatatggccccggacccggcac
cagtgccgatcagcagtctctgtacggacccggacccggggagatgaacgcccccaactatcactatctggccagctgcatgggactgatctacgac
accgtgaaccggacccaccagtacggcaccgagaagctgaccatcacatacgccttcgacgagcggcggaacaaatacgataccgtgcacgacc
ggaccccctatctgactgaagtggaaacttacgtgctgggacccggacccggcagcgtgaagaatggcacatacgactacggcaccatcaaggac
agaagcccctacaacgccgacacactgtgcatcggctatgggcccggacccgggggaatggtggatgggtggtacggctactgcaccgagctgaa
gctgagcgactatggacccggacccggcgtgtcagatggcggcccaaatctgtacgaaatctgccccaagctggccgagtacaagagctgcatcaa
ccggtgcttctaccaagtgtcccggcccatgtttctgtacggcgccaaagaagtggctctgagctacggacccggacccggcgaactggatgcccca
aactaccactacgatctgctggaaaatctgcaagcctacgccagccaaggcaccaagcggagctacaacaccgatctggaagctctgatggaaaac
atggacaaggccgtgaagctgtatctgagcaccgccagcagctggtcttacggacccggacccggcggaatgatcgacgggtggtatggatactga
tga
>Class II concatemer construct
acaagaggcgtgcagatcgccagcaacgagaacgtggaaaccatggacagcaacacactggaactgcggacatacgtgctgagcatcatcccca
gcggccctctgaaggccgagatcgcccagagactggaaagcgtgtacagatacggcttcgtggccaacttcagcatggaactgcccagcttcggcg
tgtccggctgcagaacattctttctgacacaaggcgctctgctgaacgacaagcacatcgaccccttcaagctgctgcagaatagccaagtggtgtctc
tgatgcggccctacgaggaactgcgcgagcagctgtccagcgtgtccagcttcgagcggttccaagacattctgatgcgcatgagcaagatgcagct
gggctccagcagcgagatgatgggcatgttcaatatgctgagcaccgtgctgggcgtgtccatcggcgacaagatcacattcgaggccaccggcaa
tctggtggtgccccggtacagatccaagtttctgctgatggacgctctgaagctgtccatcgaggaccctagctgcatgggactgatctacaaccggat
gggcaccgtgaccaccgaggccgcttttggactcgtgtgcttcgagcagatcactttcatgcaagctctgcagctgctgctggaagtggaaaaccaga
cttacgtgaacatcagcaacaccaacttcgccgctggccagagcgtggtgtccgtgaagctggtgcccagatacgcctttgccatggaacggaatgc
cggcagcggcatcatcatcagcgaagtgcacatctactatctggaaaaggccaacaagatcaagagcgagaaaacccacatccacatctttggcccc
ggacccggcatggccaatctgattctgcagatcggcaacatcatctccatctggatcagccactctatcgaggatctgatctttctggctcggagcgcac
tgattctgagaggcagcgtggcccacaagagctgtctgcccaccagacagatggtgcacgccatgagaaccatcggcacccaccctagctctagcg
cctccgtggtgtctgtgaaactggccggcaatagctctctgtgccccgtgtccacccggatctaccagattctggccatctacagcaccgtggcctcttc
tctggtgctcgtgtgatga
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Supplemental Table 2. Low-resolution SLA-typing results.
SLA class I
Group

Pig

NV

SLA-2

SLA-3

DRB1

DQB1

DQA

413 08XX

0901-02

05XX,0602

07XX,10XX

0201,06XX

01XX,02XX

414 08XX,15XX

12XX,16XX

0601,07XX

0401-02,0403-04

0202,0302-03

02XX

419 08XX,15XX

05XX,16XX

07XX

0403-04,10XX

06XX,07XX

01XX

420 08XX

0901-02,12XX

05XX,0601

0401-02,07XX

0201,0202

02XX

421 08XX,12XX,1301 05XX,10XX

05XX,07XX

06XX,10XX

06XX,07XX

01XX

422 08XX,15XX

12XX,16XX

0601,07XX

0401-02,0403-04

0202,0302-03

02XX

423 08XX

0901-02,12XX

05XX,0601

0401-02,07XX

0201,0202

02XX

424 08XX

12XX

0601

0401-02

0202

02XX

425 12XX,1301

10XX

05XX

06XX,10XX

06XX,07XX

01XX

426 08XX

05XX,12XX

0601,07XX

0401-02,10XX

0202,06XX

01XX,02XX

PigMatrix- 428 08XX

05XX,12XX

0601,07XX

0401-02,10XX

0202,06XX

01XX,02XX

429 08XX,12XX,1301 0901-02,12XX

05XX,0602

06XX,10XX

06XX,07XX

01XX

430 08XX

0601,07XX

0401-02,10XX

0202,06XX

01XX,02XX

431 08XX,12XX,1301 05XX,10XX

05XX,07XX

06XX,10XX

06XX,07XX

01XX

432 08XX

05XX,07XX

10XX

06XX

01XX

433 08XX,12XX,1301 0901-02,12XX

05XX,0602

06XX,10XX

06XX,07XX

01XX

434 04XX,08XX

04XX,0601

0401-02,09XX

0202,08XX

02XX,03XX

435 1103,12XX,1301 10XX,jh02

05XX

06XX

07XX

01XX

436 08XX

05XX,12XX

05XX,0601

0401-02,10XX

0202,06XX

01XX,02XX

437 12XX,1301

10XX

05XX

06XX

07XX

01XX

438 08XX,12XX,1301 05XX,12XX

05XX,0601

0401-02,06XX

0202,07XX

01XX,02XX

439 08XX

12XX

0601

0401-02

0202

02XX

440 07XX,08XX

02XX,05XX

04XX,07XX

02XX,10XX

0201,06XX

01XX,02XX

05XX

06XX

07XX

01XX

Sham

EDV

FluSure

SLA-1

SLA class II

05XX,12XX

05XX,10XX

04XX,12XX

441 1103,12XX,1301 10XX,jh02
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Supplemental information for Chapter 4
Supplemental Table 1. EpiCC scores between HA sequences of IA00 H1γ FS vaccine virus and
field viruses.
Score
Vaccine

Strain

Total

unique

unique

EpiCC

0.118 (100)

0.000

0.000

0.118

MN11 H1γ (P)

0.097 (82.2)

0.022

0.025

0.050

IA92 H1α (P)

0.092 (78.0)

0.027

0.027

0.038

OH10 H1γ (P)

0.091 (77.1)

0.028

0.028

0.036

IA15 H1γ

0.088 (74.6)

0.030

0.031

0.026

CA09 H1pdm (P)

0.087 (73.7)

0.032

0.031

0.023

MN15 H1γ

0.085 (72.0)

0.034

0.033

0.018

SH91 H1α

0.083 (70.3)

0.035

0.037

0.011

IA04 H1β

0.079 (66.9)

0.040

0.039

0.000

MN02 H1β (P)*

0.078 (66.1)

0.041

0.040

-0.002

IA12 H1γ-2

0.071 (60.2)

0.048

0.045

-0.023

IL08 H1α (PP)*

0.068 (57.6)

0.051

0.054

-0.038

IA30 cH1

0.060 (50.8)

0.060

0.060

-0.060

SD15 H1α

0.058 (49.2)

0.062

0.065

-0.068

NC05 H1δ2 FS

0.053 (44.9)

0.066

0.069

-0.082

NC05 H1δ2

0.053 (44.9)

0.066

0.069

-0.083

OK08 H1δ1 FS

0.053 (44.9)

0.066

0.070

-0.083

ON04 H1δ1

0.052 (44.1)

0.068

0.074

-0.090

IL11 H1δ1

0.050 (42.4)

0.070

0.071

-0.091

OK14 H1δ1

0.052 (44.1)

0.068

0.076

-0.092

SD15 H1δ1

0.049 (41.5)

0.071

0.073

-0.095

IA15 H1δ1

0.049 (41.5)

0.071

0.081

-0.103

MN15b H1δ1

0.048 (40.7)

0.072

0.083

-0.107

MN15a H1δ1

0.043 (36.4)

0.077

0.083

-0.117

Straina

Shared (%)b

IA00 H1γ FS

a

FS γ-cluster vaccine strain was protective or partially protective against challenge with viruses
annotated as (P) or (PP), respectively. Viruses used to set the thresholds are marked with an asterisk (*).
b
Ratio of the score of shared epitopes relative to the baseline EpiCC scores expressed as percentage.
Table is sorted by total EpiCC score. Strains below the total EpiCC score threshold associated with
partial protection are shown in gray.
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Supplemental Fig. 1. Comparison of HA baseline EpiCC score by set of MHC alleles.

**

**

*

*

Baseline EpiCC score of HA sequences of each virus (E(s,s)A) was determined using predictions for
swine and human class I and II MHC alleles (SLA-I: 8 alleles, SLA-II: 5 alleles, HLA-I: 6 alleles, and
HLA-II: 8 alleles). P-values of comparisons were calculated using one-tailed Wilcoxon matched-pairs
signed rank test (**p<0.001, *p<0.05).

121

Supplemental Fig. 2. Comparison of scores of shared and unique epitopes across strains.

*

**

**

**

**

*

Strain
1:IA00 H1γ FS

4:OH10 H1γ

7:IA15 H1γ

10:SH91 H1α

13:SD15 H1α

16:NC05 H1δ2

19:IL11 H1δ1

22:IA15 H1δ1

2:IA92 H1α

5:CA09 H1pdm

8:IA04 H1β

11:MN15 H1γ

14:IA30 cH1

17:OK08 H1δ1 FS

20:OK14 H1δ1

23:SD15 H1δ1

3:MN11 H1γ

6:IA12 H1γ-2

9:MN02 H1β

12:IL08 H1α

15:NC05 H1δ2 FS

18:ON04 H1δ1

21:MN15a H1δ1

24:MN15b H1δ1

Scores of shared, vaccine unique and strain unique HLA class I and II epitopes were determined for the
comparison of HA sequences from vaccine viruses and field (challenge) strains. Note that y-axes show
different scales. Solid connecting lines are included only for visualization purposes. P-values of
comparisons were calculated using one-tailed Wilcoxon matched-pairs signed rank test (**p<0.001,
*p<0.05). HA vaccine sequences had higher scores for shared epitopes with strains belonging to the
same H1 cluster or the same HA lineage. Scores of class II shared epitopes were significantly higher
than those of class I. Class II scores of unique epitopes were also higher for OK08 H1δ1 FS (vaccine
unique) and NC05 H1δ2 FS (strain unique). In contrast, class I scores of IA00 H1γ FS vaccine unique
epitopes were higher than those of class II, which is explained by the higher baseline EpiCC score of
the vaccine. Viruses are sorted by nucleotide identity relative to H1γ FS. Strain numbers on the x-axis
are described in detail in the legend below.
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Supplemental Fig. 3. Relationship between EpiCC scores and nucleotide identity.

R2 = 0.97

R2 = 0.98

R2 = 0.96

R2 = 0.93

R2 = 0.96

R2 = 0.96

The second order polynomial relationship between class I (top), II (bottom) EpiCC scores, and
nucleotide identity for each FS virus are shown. R2 of regression models are shown. H3N2, H4N6 and a
random sequence were included in this analysis to represent the lower end of the identity range. Class I
and II EpiCC scores correlated with identity between HA nucleotide sequences of vaccines and viral
strains (r=0.89 – 0.90). However, their relationship was non linear; instead, it was second order
polynomial (R2=0.93 – 0.98). EpiCC score was close to the lowest at approximately 50% identity.
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